JP2000512641A - 1,2,4―ベンゾチアジアジン誘導体、その製造および使用 - Google Patents
1,2,4―ベンゾチアジアジン誘導体、その製造および使用Info
- Publication number
- JP2000512641A JP2000512641A JP10502127A JP50212798A JP2000512641A JP 2000512641 A JP2000512641 A JP 2000512641A JP 10502127 A JP10502127 A JP 10502127A JP 50212798 A JP50212798 A JP 50212798A JP 2000512641 A JP2000512641 A JP 2000512641A
- Authority
- JP
- Japan
- Prior art keywords
- benzothiadiazine
- dioxide
- chloro
- amino
- isopropylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 150000008349 1,2,4-benzothiadiazines Chemical class 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 226
- 238000000034 method Methods 0.000 claims abstract description 121
- 239000000203 mixture Substances 0.000 claims abstract description 77
- -1 nitro, amino Chemical group 0.000 claims description 285
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 54
- 229910052736 halogen Inorganic materials 0.000 claims description 52
- 150000002367 halogens Chemical class 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical class 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- 230000003287 optical effect Effects 0.000 claims description 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 10
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 10
- 201000008980 hyperinsulinism Diseases 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 102000004257 Potassium Channel Human genes 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical class 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 108020001213 potassium channel Proteins 0.000 claims description 8
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical class 0.000 claims description 7
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 5
- BOBJIMXINQEKDG-UHFFFAOYSA-N 1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=CC=C2NC(N)=NS(=O)(=O)C2=C1 BOBJIMXINQEKDG-UHFFFAOYSA-N 0.000 claims description 5
- 208000017701 Endocrine disease Diseases 0.000 claims description 5
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 5
- 125000005110 aryl thio group Chemical group 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000001072 heteroaryl group Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 4
- OTPWEBAPPVJWHH-UHFFFAOYSA-N 1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 OTPWEBAPPVJWHH-UHFFFAOYSA-N 0.000 claims description 4
- PBAZKPXHKDHPED-UHFFFAOYSA-N 1,1-dioxo-n-propan-2-yl-7-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC(F)(F)C1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 PBAZKPXHKDHPED-UHFFFAOYSA-N 0.000 claims description 4
- UKFTVRNKWVNYPL-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)N)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)N)C=C1 UKFTVRNKWVNYPL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 claims description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 3
- FRPFLQNWCHQUFS-UHFFFAOYSA-N 1,1-dioxo-n-propan-2-yl-6-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(C(F)(F)F)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 FRPFLQNWCHQUFS-UHFFFAOYSA-N 0.000 claims description 3
- XKWMCTLTNJLLGO-UHFFFAOYSA-N 1,1-dioxo-n-propyl-7-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC(F)(F)C1=CC=C2NC(NCCC)=NS(=O)(=O)C2=C1 XKWMCTLTNJLLGO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims description 3
- USFHNPHMDUXSEW-UHFFFAOYSA-N 2-[1,1-dioxo-3-(propan-2-ylamino)-4h-1$l^{6},2,4-benzothiadiazin-6-yl]acetic acid Chemical compound C1=C(CC(O)=O)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 USFHNPHMDUXSEW-UHFFFAOYSA-N 0.000 claims description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 3
- KOFMRKRRRFRITI-UHFFFAOYSA-N 6,7-dichloro-N-hexyl-4H-1,2,4-benzothiadiazin-3-imine Chemical compound ClC1=C(Cl)C=C2SNC(NCCCCCC)=NC2=C1 KOFMRKRRRFRITI-UHFFFAOYSA-N 0.000 claims description 3
- XRQUAFKCGFTBOB-UHFFFAOYSA-N 6-chloro-7-fluoro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC1=C(Cl)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 XRQUAFKCGFTBOB-UHFFFAOYSA-N 0.000 claims description 3
- XNZTYQNDMXWYDL-UHFFFAOYSA-N 6-chloro-n-(cyclopropylmethyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(Cl)=CC=C(S(N=2)(=O)=O)C=1NC=2NCC1CC1 XNZTYQNDMXWYDL-UHFFFAOYSA-N 0.000 claims description 3
- KPVHPSDVHHGAKO-UHFFFAOYSA-N 6-chloro-n-hexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NCCCCCC)=NS(=O)(=O)C2=C1 KPVHPSDVHHGAKO-UHFFFAOYSA-N 0.000 claims description 3
- DWMQPXADHJEGHW-UHFFFAOYSA-N 6-fluoro-n-propan-2-yl-2h-1,2,4-benzothiadiazin-3-amine Chemical compound FC1=CC=C2SNC(NC(C)C)=NC2=C1 DWMQPXADHJEGHW-UHFFFAOYSA-N 0.000 claims description 3
- VLQYAGJAPZZHOF-UHFFFAOYSA-N 6-methylsulfonyl-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(S(C)(=O)=O)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 VLQYAGJAPZZHOF-UHFFFAOYSA-N 0.000 claims description 3
- QARSHKHBADCIEA-UHFFFAOYSA-N 7-bromo-1,1-dioxo-n-propyl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound BrC1=CC=C2NC(NCCC)=NS(=O)(=O)C2=C1 QARSHKHBADCIEA-UHFFFAOYSA-N 0.000 claims description 3
- CHJACOKBOMFGAH-UHFFFAOYSA-N 7-bromo-n-ethyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound BrC1=CC=C2NC(NCC)=NS(=O)(=O)C2=C1 CHJACOKBOMFGAH-UHFFFAOYSA-N 0.000 claims description 3
- GIPZVQADKAGZKC-UHFFFAOYSA-N 7-bromo-n-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound BrC1=CC=C2NC(NC)=NS(=O)(=O)C2=C1 GIPZVQADKAGZKC-UHFFFAOYSA-N 0.000 claims description 3
- VKBBUVNWYTXRJC-UHFFFAOYSA-N 7-chloro-1,1-dioxo-3-(2,2,2-trifluoroethyl)-1lambda6,2,4-benzothiadiazin-4-amine Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)CC(F)(F)F)N)C=C1 VKBBUVNWYTXRJC-UHFFFAOYSA-N 0.000 claims description 3
- WIBBVGZUMKYDRC-UHFFFAOYSA-N 7-chloro-1,1-dioxo-n-phenyl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(Cl)=CC=C2NC=1NC1=CC=CC=C1 WIBBVGZUMKYDRC-UHFFFAOYSA-N 0.000 claims description 3
- GEACXCCDRHBNCQ-UHFFFAOYSA-N 7-chloro-n-(cyclopropylmethyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(Cl)=CC=C2NC=1NCC1CC1 GEACXCCDRHBNCQ-UHFFFAOYSA-N 0.000 claims description 3
- WSLROIYLWIJDGH-UHFFFAOYSA-N 7-chloro-n-hexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(NCCCCCC)=NS(=O)(=O)C2=C1 WSLROIYLWIJDGH-UHFFFAOYSA-N 0.000 claims description 3
- QYLRSKDLBNBVJX-UHFFFAOYSA-N 7-fluoro-1,1-dioxo-3-(2,2,2-trifluoroethyl)-1lambda6,2,4-benzothiadiazin-4-amine Chemical compound FC1=CC2=C(N(C(=NS2(=O)=O)CC(F)(F)F)N)C=C1 QYLRSKDLBNBVJX-UHFFFAOYSA-N 0.000 claims description 3
- CIDUUXVAZLSDHO-UHFFFAOYSA-N 7-fluoro-1,1-dioxo-n-propyl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC1=CC=C2NC(NCCC)=NS(=O)(=O)C2=C1 CIDUUXVAZLSDHO-UHFFFAOYSA-N 0.000 claims description 3
- HLGIAAJOLCNVPG-UHFFFAOYSA-N 7-methoxy-n-propan-2-yl-2h-1,2,4-benzothiadiazin-3-amine Chemical compound N1C(NC(C)C)=NSC2=CC(OC)=CC=C21 HLGIAAJOLCNVPG-UHFFFAOYSA-N 0.000 claims description 3
- SZHJIMDAHOXCLM-UHFFFAOYSA-N 7-tert-butyl-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound CC(C)(C)C1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 SZHJIMDAHOXCLM-UHFFFAOYSA-N 0.000 claims description 3
- KRJMKKIWTQLOES-UHFFFAOYSA-N C1=CC2=C(C=C1Br)S(=O)(=O)N=C(N2N)CC(F)(F)F Chemical compound C1=CC2=C(C=C1Br)S(=O)(=O)N=C(N2N)CC(F)(F)F KRJMKKIWTQLOES-UHFFFAOYSA-N 0.000 claims description 3
- YSLPBGBONYPHEW-UHFFFAOYSA-N C1=CC2=C(C=C1Cl)N(C(=NS2(=O)=O)CC(F)(F)F)N Chemical compound C1=CC2=C(C=C1Cl)N(C(=NS2(=O)=O)CC(F)(F)F)N YSLPBGBONYPHEW-UHFFFAOYSA-N 0.000 claims description 3
- WRQGHWKQEHAVCX-UHFFFAOYSA-N CC(C)C(C)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Br Chemical compound CC(C)C(C)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Br WRQGHWKQEHAVCX-UHFFFAOYSA-N 0.000 claims description 3
- WANOYVIYOQAPAU-UHFFFAOYSA-N CC(C)C(C)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)I Chemical compound CC(C)C(C)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)I WANOYVIYOQAPAU-UHFFFAOYSA-N 0.000 claims description 3
- OYFPKJNOUQTGCM-UHFFFAOYSA-N CC(C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)I)C(C)(C)C Chemical compound CC(C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)I)C(C)(C)C OYFPKJNOUQTGCM-UHFFFAOYSA-N 0.000 claims description 3
- FRWKRWHTCSNJFU-UHFFFAOYSA-N CC(CC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl)O Chemical compound CC(CC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl)O FRWKRWHTCSNJFU-UHFFFAOYSA-N 0.000 claims description 3
- SMYTYIOZPRDQSG-UHFFFAOYSA-N CCC(CC)C(N(C1=C2C=CC(Cl)=C1)N)=NS2(=O)=O Chemical compound CCC(CC)C(N(C1=C2C=CC(Cl)=C1)N)=NS2(=O)=O SMYTYIOZPRDQSG-UHFFFAOYSA-N 0.000 claims description 3
- UCLAJEKYVHKIRM-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)C(CC)CC)N)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)C(CC)CC)N)C=C1 UCLAJEKYVHKIRM-UHFFFAOYSA-N 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 3
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004671 dialkylaminothiocarbonyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 3
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- CUXSJLRQLJOVIH-UHFFFAOYSA-N n-[1,1-dioxo-3-(propan-2-ylamino)-4h-1$l^{6},2,4-benzothiadiazin-7-yl]acetamide Chemical compound CC(=O)NC1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 CUXSJLRQLJOVIH-UHFFFAOYSA-N 0.000 claims description 3
- USANRYZKXFZARO-UHFFFAOYSA-N n-[2-[(7-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-yl)amino]ethyl]formamide Chemical compound N1C(NCCNC=O)=NS(=O)(=O)C2=CC(Cl)=CC=C21 USANRYZKXFZARO-UHFFFAOYSA-N 0.000 claims description 3
- QXGMRSQJEZVABW-UHFFFAOYSA-N n-benzyl-7-iodo-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(I)=CC=C2NC=1NCC1=CC=CC=C1 QXGMRSQJEZVABW-UHFFFAOYSA-N 0.000 claims description 3
- UMWQSOWVQUCGLP-UHFFFAOYSA-N n-butyl-6-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NCCCC)=NS(=O)(=O)C2=C1 UMWQSOWVQUCGLP-UHFFFAOYSA-N 0.000 claims description 3
- DVSNVHUODBAGDK-UHFFFAOYSA-N n-ethyl-7-fluoro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC1=CC=C2NC(NCC)=NS(=O)(=O)C2=C1 DVSNVHUODBAGDK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- SIVOLYZZWQIMOC-UHFFFAOYSA-N 1,1-dioxo-3-(propan-2-ylamino)-4h-1$l^{6},2,4-benzothiadiazine-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 SIVOLYZZWQIMOC-UHFFFAOYSA-N 0.000 claims description 2
- IJMJHCOXZKBQEX-UHFFFAOYSA-N 1,1-dioxo-3-(propan-2-ylamino)-4h-1$l^{6},2,4-benzothiadiazine-7-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 IJMJHCOXZKBQEX-UHFFFAOYSA-N 0.000 claims description 2
- SMFJRXIRZMABPM-UHFFFAOYSA-N 1,1-dioxo-6-phenoxy-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C2NC(NC(C)C)=NS(=O)(=O)C2=CC=C1OC1=CC=CC=C1 SMFJRXIRZMABPM-UHFFFAOYSA-N 0.000 claims description 2
- KLJXQVRYJZYYGJ-UHFFFAOYSA-N 1,1-dioxo-n,6-di(propan-2-yl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(C(C)C)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 KLJXQVRYJZYYGJ-UHFFFAOYSA-N 0.000 claims description 2
- KCVQIVVCJCYHBK-UHFFFAOYSA-N 1,1-dioxo-n-propan-2-yl-6,8-bis(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(C(F)(F)F)C=C(C(F)(F)F)C2=C1NC(NC(C)C)=NS2(=O)=O KCVQIVVCJCYHBK-UHFFFAOYSA-N 0.000 claims description 2
- CAPAASCIRYIBJQ-UHFFFAOYSA-N 2-[1,1-dioxo-3-(propan-2-ylamino)-4h-1$l^{6},2,4-benzothiadiazin-6-yl]acetonitrile Chemical compound C1=C(CC#N)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 CAPAASCIRYIBJQ-UHFFFAOYSA-N 0.000 claims description 2
- ZVZBNUVZBPMKQD-UHFFFAOYSA-N 3-n-(7-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-yl)-1-n,1-n-diethylbutane-1,3-diamine Chemical compound ClC1=CC=C2NC(NC(C)CCN(CC)CC)=NS(=O)(=O)C2=C1 ZVZBNUVZBPMKQD-UHFFFAOYSA-N 0.000 claims description 2
- QRGAFRSTXHLLPY-UHFFFAOYSA-N 3-propylimino-4H-1,2,4-benzothiadiazine-7-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2SNC(NCCC)=NC2=C1 QRGAFRSTXHLLPY-UHFFFAOYSA-N 0.000 claims description 2
- BBNGVMNBBLPZIR-UHFFFAOYSA-N 4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)N=CNC2=C1 BBNGVMNBBLPZIR-UHFFFAOYSA-N 0.000 claims description 2
- LLZMLUUOUTYGSB-UHFFFAOYSA-N 5,7-dibromo-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound BrC1=CC(Br)=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 LLZMLUUOUTYGSB-UHFFFAOYSA-N 0.000 claims description 2
- SMCPGWWUKBDGRC-UHFFFAOYSA-N 5-chloro-1,1-dioxo-n-propyl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=CC(Cl)=C2NC(NCCC)=NS(=O)(=O)C2=C1 SMCPGWWUKBDGRC-UHFFFAOYSA-N 0.000 claims description 2
- FTWVFRKJJSIWRA-UHFFFAOYSA-N 5-chloro-n-hexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=CC(Cl)=C2NC(NCCCCCC)=NS(=O)(=O)C2=C1 FTWVFRKJJSIWRA-UHFFFAOYSA-N 0.000 claims description 2
- XLLSHIVYFYTWRM-UHFFFAOYSA-N 6,7,8-trifluoro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(F)C(F)=C(F)C2=C1NC(NC(C)C)=NS2(=O)=O XLLSHIVYFYTWRM-UHFFFAOYSA-N 0.000 claims description 2
- GJVBUSAZTDCLNF-UHFFFAOYSA-N 6,7-dichloro-1,1-dioxo-n-pentan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=C(Cl)C=C2NC(NC(C)CCC)=NS(=O)(=O)C2=C1 GJVBUSAZTDCLNF-UHFFFAOYSA-N 0.000 claims description 2
- FWEWSAZHNTVYFX-UHFFFAOYSA-N 6,7-dichloro-n-cyclobutyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2NC=1NC1CCC1 FWEWSAZHNTVYFX-UHFFFAOYSA-N 0.000 claims description 2
- LIFGFDUZGAHMME-UHFFFAOYSA-N 6,7-dichloro-n-cyclopropyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2NC=1NC1CC1 LIFGFDUZGAHMME-UHFFFAOYSA-N 0.000 claims description 2
- WRBQGMGYUTVLFN-UHFFFAOYSA-N 6,7-difluoro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC1=C(F)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 WRBQGMGYUTVLFN-UHFFFAOYSA-N 0.000 claims description 2
- KLBXVIIYMKOZLT-UHFFFAOYSA-N 6,7-dimethoxy-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N1C(NC(C)C)=NS(=O)(=O)C2=C1C=C(OC)C(OC)=C2 KLBXVIIYMKOZLT-UHFFFAOYSA-N 0.000 claims description 2
- GCPPXRRBOVNQEL-UHFFFAOYSA-N 6,8-dichloro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1Cl GCPPXRRBOVNQEL-UHFFFAOYSA-N 0.000 claims description 2
- GMDSIEBJJCURCD-UHFFFAOYSA-N 6,8-dichloro-n-(cyclopropylmethyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(Cl)=CC(Cl)=C(S(N=2)(=O)=O)C=1NC=2NCC1CC1 GMDSIEBJJCURCD-UHFFFAOYSA-N 0.000 claims description 2
- GBTSHZDYTUEMCA-UHFFFAOYSA-N 6,8-dichloro-n-cyclobutyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(Cl)=CC(Cl)=C(S(N=2)(=O)=O)C=1NC=2NC1CCC1 GBTSHZDYTUEMCA-UHFFFAOYSA-N 0.000 claims description 2
- CYIIKXVTSZAZRL-UHFFFAOYSA-N 6,8-dichloro-n-cyclopentyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(Cl)=CC(Cl)=C(S(N=2)(=O)=O)C=1NC=2NC1CCCC1 CYIIKXVTSZAZRL-UHFFFAOYSA-N 0.000 claims description 2
- YIMTYJNNEYFVCI-UHFFFAOYSA-N 6,8-dichloro-n-cyclopropyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(Cl)=CC(Cl)=C(S(N=2)(=O)=O)C=1NC=2NC1CC1 YIMTYJNNEYFVCI-UHFFFAOYSA-N 0.000 claims description 2
- KGSQECHHSOYQQQ-UHFFFAOYSA-N 6,8-dichloro-n-ethyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NCC)=NS(=O)(=O)C2=C1Cl KGSQECHHSOYQQQ-UHFFFAOYSA-N 0.000 claims description 2
- YBESNBHFXSUHEH-UHFFFAOYSA-N 6,8-difluoro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(F)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1F YBESNBHFXSUHEH-UHFFFAOYSA-N 0.000 claims description 2
- NTAKQZCUDFKDKS-UHFFFAOYSA-N 6-(benzenesulfonyl)-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C2NC(NC(C)C)=NS(=O)(=O)C2=CC=C1S(=O)(=O)C1=CC=CC=C1 NTAKQZCUDFKDKS-UHFFFAOYSA-N 0.000 claims description 2
- TZBFHUKTVWGEPT-UHFFFAOYSA-N 6-chloro-7-methyl-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound CC1=C(Cl)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 TZBFHUKTVWGEPT-UHFFFAOYSA-N 0.000 claims description 2
- RKRXRWKNCWSXPC-UHFFFAOYSA-N 6-chloro-n-(2-methylpropyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NCC(C)C)=NS(=O)(=O)C2=C1 RKRXRWKNCWSXPC-UHFFFAOYSA-N 0.000 claims description 2
- ZIUFAFFUXDUHEG-UHFFFAOYSA-N 6-chloro-n-(3,3-dimethylbutan-2-yl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NC(C)C(C)(C)C)=NS(=O)(=O)C2=C1 ZIUFAFFUXDUHEG-UHFFFAOYSA-N 0.000 claims description 2
- AQWLLKSPYAIJDY-UHFFFAOYSA-N 6-chloro-n-cyclopropyl-2h-1,2,4-benzothiadiazin-3-amine Chemical compound N=1C2=CC(Cl)=CC=C2SNC=1NC1CC1 AQWLLKSPYAIJDY-UHFFFAOYSA-N 0.000 claims description 2
- BABLYRYOHHNFOE-UHFFFAOYSA-N 6-chloro-n-methoxy-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NOC)=NS(=O)(=O)C2=C1 BABLYRYOHHNFOE-UHFFFAOYSA-N 0.000 claims description 2
- IIJBGXBPEICHAL-UHFFFAOYSA-N 7-chloro-1,1-dioxo-3-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazine-3,5-diamine Chemical compound ClC1=CC(N)=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 IIJBGXBPEICHAL-UHFFFAOYSA-N 0.000 claims description 2
- QNGQFBHEQJKTRH-UHFFFAOYSA-N 7-chloro-1,1-dioxo-n-(4-phenylbutyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(Cl)=CC=C2NC=1NCCCCC1=CC=CC=C1 QNGQFBHEQJKTRH-UHFFFAOYSA-N 0.000 claims description 2
- KVSHJIYNUBZUDO-UHFFFAOYSA-N 7-chloro-5-nitro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC([N+]([O-])=O)=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 KVSHJIYNUBZUDO-UHFFFAOYSA-N 0.000 claims description 2
- CUUORSSQBNYMAH-UHFFFAOYSA-N 7-chloro-6-methoxy-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N1C(NC(C)C)=NS(=O)(=O)C2=C1C=C(OC)C(Cl)=C2 CUUORSSQBNYMAH-UHFFFAOYSA-N 0.000 claims description 2
- CHQCUCBETBYQQT-UHFFFAOYSA-N 7-chloro-n-(3,3-dimethylbutan-2-yl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(NC(C)C(C)(C)C)=NS(=O)(=O)C2=C1 CHQCUCBETBYQQT-UHFFFAOYSA-N 0.000 claims description 2
- XFQFVWNZGCWZSB-UHFFFAOYSA-N 7-chloro-n-(3,3-diphenylpropyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(Cl)=CC=C2NC=1NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 XFQFVWNZGCWZSB-UHFFFAOYSA-N 0.000 claims description 2
- RSFDRWRVUMSLJP-UHFFFAOYSA-N 7-chloro-n-(cyclohexylmethyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(Cl)=CC=C2NC=1NCC1CCCCC1 RSFDRWRVUMSLJP-UHFFFAOYSA-N 0.000 claims description 2
- UOQPZWZLFHJLAI-UHFFFAOYSA-N 7-chloro-n-cyclopropyl-2h-1,2,4-benzothiadiazin-3-amine Chemical compound N1SC2=CC(Cl)=CC=C2N=C1NC1CC1 UOQPZWZLFHJLAI-UHFFFAOYSA-N 0.000 claims description 2
- PNMRNEJACLTTNC-UHFFFAOYSA-N 7-chloro-n-ethyl-n-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(N(C)CC)=NS(=O)(=O)C2=C1 PNMRNEJACLTTNC-UHFFFAOYSA-N 0.000 claims description 2
- NSCQVZVTYXTOKQ-UHFFFAOYSA-N 7-chloro-n-methoxy-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(NOC)=NS(=O)(=O)C2=C1 NSCQVZVTYXTOKQ-UHFFFAOYSA-N 0.000 claims description 2
- CIKRYYGIMSKEPA-UHFFFAOYSA-N 7-fluoro-1,1-dioxo-3-n,6-n-di(propan-2-yl)-4h-1$l^{6},2,4-benzothiadiazine-3,6-diamine Chemical compound FC1=C(NC(C)C)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 CIKRYYGIMSKEPA-UHFFFAOYSA-N 0.000 claims description 2
- OOXJYBXEHJKBRE-UHFFFAOYSA-N 7-fluoro-6-methyl-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC1=C(C)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 OOXJYBXEHJKBRE-UHFFFAOYSA-N 0.000 claims description 2
- PJHFBLBJDHHHNR-UHFFFAOYSA-N 7-fluoro-n-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC1=CC=C2NC(NC)=NS(=O)(=O)C2=C1 PJHFBLBJDHHHNR-UHFFFAOYSA-N 0.000 claims description 2
- KIHRSBIKAAPZEH-UHFFFAOYSA-N 7-methoxy-1,1-dioxo-n-propyl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound COC1=CC=C2NC(NCCC)=NS(=O)(=O)C2=C1 KIHRSBIKAAPZEH-UHFFFAOYSA-N 0.000 claims description 2
- CBUSLMDFVVDNCJ-UHFFFAOYSA-N 7-methyl-n-(2-methylpropyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound CC1=CC=C2NC(NCC(C)C)=NS(=O)(=O)C2=C1 CBUSLMDFVVDNCJ-UHFFFAOYSA-N 0.000 claims description 2
- ABBNLJJWGBKSPH-UHFFFAOYSA-N 7-nitro-1,1-dioxo-n-propyl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound [O-][N+](=O)C1=CC=C2NC(NCCC)=NS(=O)(=O)C2=C1 ABBNLJJWGBKSPH-UHFFFAOYSA-N 0.000 claims description 2
- FRJFYPFQQROXGW-UHFFFAOYSA-N 8-chloro-N-propan-2-yl-4H-1,2,4-benzothiadiazin-3-imine Chemical compound C1=CC(Cl)=C2SNC(NC(C)C)=NC2=C1 FRJFYPFQQROXGW-UHFFFAOYSA-N 0.000 claims description 2
- WMUVEVQBGARZMA-UHFFFAOYSA-N CC(=O)NCCC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl Chemical compound CC(=O)NCCC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl WMUVEVQBGARZMA-UHFFFAOYSA-N 0.000 claims description 2
- YSZDUQAYUQXEGN-UHFFFAOYSA-N CC(C)CCC(C)C(N(C1=C2C(C(F)(F)F)=CC(C(F)(F)F)=C1)N)=NS2(=O)=O Chemical compound CC(C)CCC(C)C(N(C1=C2C(C(F)(F)F)=CC(C(F)(F)F)=C1)N)=NS2(=O)=O YSZDUQAYUQXEGN-UHFFFAOYSA-N 0.000 claims description 2
- MCABBOCVIRNAOW-UHFFFAOYSA-N CCC(CC)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)I Chemical compound CCC(CC)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)I MCABBOCVIRNAOW-UHFFFAOYSA-N 0.000 claims description 2
- RMTNFSYIIKLEBJ-UHFFFAOYSA-N CCNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=CC=N3 Chemical compound CCNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=CC=N3 RMTNFSYIIKLEBJ-UHFFFAOYSA-N 0.000 claims description 2
- SNNYRIMVWNOVLU-UHFFFAOYSA-N CCNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 Chemical compound CCNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 SNNYRIMVWNOVLU-UHFFFAOYSA-N 0.000 claims description 2
- QIVSSXBXKZSWOW-UHFFFAOYSA-N CCNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=CC=N3 Chemical compound CCNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=CC=N3 QIVSSXBXKZSWOW-UHFFFAOYSA-N 0.000 claims description 2
- FOOVFZXCVCNLSV-UHFFFAOYSA-N CCNN1C2=C(C=CC(=C2)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 Chemical compound CCNN1C2=C(C=CC(=C2)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 FOOVFZXCVCNLSV-UHFFFAOYSA-N 0.000 claims description 2
- PHYMUMQVXQCVRE-UHFFFAOYSA-N CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=CC=N3)Cl)Cl Chemical compound CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=CC=N3)Cl)Cl PHYMUMQVXQCVRE-UHFFFAOYSA-N 0.000 claims description 2
- ZGJJHFYHLXRFAY-UHFFFAOYSA-N CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=CC=N3)F)F Chemical compound CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=CC=N3)F)F ZGJJHFYHLXRFAY-UHFFFAOYSA-N 0.000 claims description 2
- BSJOSIPHPNQSIO-UHFFFAOYSA-N CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)Cl)Cl Chemical compound CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)Cl)Cl BSJOSIPHPNQSIO-UHFFFAOYSA-N 0.000 claims description 2
- ZBCRBCCBNPODHO-UHFFFAOYSA-N CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)F)F Chemical compound CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)F)F ZBCRBCCBNPODHO-UHFFFAOYSA-N 0.000 claims description 2
- VFGXLWRBPWWSKL-UHFFFAOYSA-N CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CN=CC=C3)F)F Chemical compound CCNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CN=CC=C3)F)F VFGXLWRBPWWSKL-UHFFFAOYSA-N 0.000 claims description 2
- KWAVICTUGSBEEH-UHFFFAOYSA-N CCOC(CC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl)OCC Chemical compound CCOC(CC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl)OCC KWAVICTUGSBEEH-UHFFFAOYSA-N 0.000 claims description 2
- WSHGFSNYXXHHEN-UHFFFAOYSA-N CCOC(CC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)F)OCC Chemical compound CCOC(CC1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)F)OCC WSHGFSNYXXHHEN-UHFFFAOYSA-N 0.000 claims description 2
- VINUIFKFXNPKTK-UHFFFAOYSA-N CNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=CC=N3 Chemical compound CNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=CC=N3 VINUIFKFXNPKTK-UHFFFAOYSA-N 0.000 claims description 2
- OHATUMKAGIQFMX-UHFFFAOYSA-N CNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=NC=C3 Chemical compound CNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=NC=C3 OHATUMKAGIQFMX-UHFFFAOYSA-N 0.000 claims description 2
- SWMVDSYHXHDALU-UHFFFAOYSA-N CNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 Chemical compound CNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 SWMVDSYHXHDALU-UHFFFAOYSA-N 0.000 claims description 2
- SCNUHRHJIVRVEG-UHFFFAOYSA-N CNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=CC=N3 Chemical compound CNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=CC=N3 SCNUHRHJIVRVEG-UHFFFAOYSA-N 0.000 claims description 2
- JIIXWUXPNYTIOX-UHFFFAOYSA-N CNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=NC=C3 Chemical compound CNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=NC=C3 JIIXWUXPNYTIOX-UHFFFAOYSA-N 0.000 claims description 2
- CDNLBFFOLREXGK-UHFFFAOYSA-N CNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CN=CC=C3 Chemical compound CNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CN=CC=C3 CDNLBFFOLREXGK-UHFFFAOYSA-N 0.000 claims description 2
- BXSNLULHVSPSQS-UHFFFAOYSA-N CNN1C2=C(C=C(C=C2)Cl)S(=O)(=O)N=C1C3=CC=NC=C3 Chemical compound CNN1C2=C(C=C(C=C2)Cl)S(=O)(=O)N=C1C3=CC=NC=C3 BXSNLULHVSPSQS-UHFFFAOYSA-N 0.000 claims description 2
- MIKOUEQLBMDQBF-UHFFFAOYSA-N CNN1C2=C(C=CC(=C2)Cl)S(=O)(=O)N=C1C3=CC=CC=N3 Chemical compound CNN1C2=C(C=CC(=C2)Cl)S(=O)(=O)N=C1C3=CC=CC=N3 MIKOUEQLBMDQBF-UHFFFAOYSA-N 0.000 claims description 2
- KYBHFULCZHTYDX-UHFFFAOYSA-N CNN1C2=C(C=CC(=C2)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 Chemical compound CNN1C2=C(C=CC(=C2)Cl)S(=O)(=O)N=C1C3=CN=CC=C3 KYBHFULCZHTYDX-UHFFFAOYSA-N 0.000 claims description 2
- FDTRKOBGQTYDPN-UHFFFAOYSA-N CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)Cl)Cl Chemical compound CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)Cl)Cl FDTRKOBGQTYDPN-UHFFFAOYSA-N 0.000 claims description 2
- SKEXJXQFPFYPDJ-UHFFFAOYSA-N CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)F)F Chemical compound CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=NC=C3)F)F SKEXJXQFPFYPDJ-UHFFFAOYSA-N 0.000 claims description 2
- NCBAVBUKQOQXEQ-UHFFFAOYSA-N CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CN=CC=C3)Cl)Cl Chemical compound CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CN=CC=C3)Cl)Cl NCBAVBUKQOQXEQ-UHFFFAOYSA-N 0.000 claims description 2
- AIHFRSAQOHWVMY-UHFFFAOYSA-N CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CN=CC=C3)F)F Chemical compound CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CN=CC=C3)F)F AIHFRSAQOHWVMY-UHFFFAOYSA-N 0.000 claims description 2
- NZTRLNSOSHTMFG-JTQLQIEISA-N C[C@@H](C1=CC=CC=C1)C2=NS(=O)(=O)C3=C(N2N)C=CC(=C3)Cl Chemical compound C[C@@H](C1=CC=CC=C1)C2=NS(=O)(=O)C3=C(N2N)C=CC(=C3)Cl NZTRLNSOSHTMFG-JTQLQIEISA-N 0.000 claims description 2
- ZRNHPSZMUQNPBM-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)C2=CC=NC=C2)NCC)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)C2=CC=NC=C2)NCC)C=C1 ZRNHPSZMUQNPBM-UHFFFAOYSA-N 0.000 claims description 2
- INSDLHMMJXFPIK-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NC)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NC)C=C1 INSDLHMMJXFPIK-UHFFFAOYSA-N 0.000 claims description 2
- FYGNBVNGGUMVCT-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NCC)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NCC)C=C1 FYGNBVNGGUMVCT-UHFFFAOYSA-N 0.000 claims description 2
- SCJWNQDEZJKWMD-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NC)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NC)C=C1 SCJWNQDEZJKWMD-UHFFFAOYSA-N 0.000 claims description 2
- BVQGAWOAYHDLBS-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NCC)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NCC)C=C1 BVQGAWOAYHDLBS-UHFFFAOYSA-N 0.000 claims description 2
- OXWUJXDFNOGMRZ-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)CCC2=CC=CC=C2)N)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)CCC2=CC=CC=C2)N)C=C1 OXWUJXDFNOGMRZ-UHFFFAOYSA-N 0.000 claims description 2
- NZTRLNSOSHTMFG-SNVBAGLBSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)[C@H](C)C2=CC=CC=C2)N)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)[C@H](C)C2=CC=CC=C2)N)C=C1 NZTRLNSOSHTMFG-SNVBAGLBSA-N 0.000 claims description 2
- XOCQBZTYXDYETI-UHFFFAOYSA-N ClC=1C(=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NCC)C1)Cl Chemical compound ClC=1C(=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NCC)C1)Cl XOCQBZTYXDYETI-UHFFFAOYSA-N 0.000 claims description 2
- ZLATVXOYMPVLJZ-UHFFFAOYSA-N ClC=1C=CC2=C(N(C(=NS2(=O)=O)C2=CC=NC=C2)NCC)C1 Chemical compound ClC=1C=CC2=C(N(C(=NS2(=O)=O)C2=CC=NC=C2)NCC)C1 ZLATVXOYMPVLJZ-UHFFFAOYSA-N 0.000 claims description 2
- AKYYZTLAVUDXPM-UHFFFAOYSA-N ClC=1C=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NCC)C1 Chemical compound ClC=1C=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NCC)C1 AKYYZTLAVUDXPM-UHFFFAOYSA-N 0.000 claims description 2
- OAQZZPXWKCHVKQ-UHFFFAOYSA-N FC1=CC2=C(N(C(=NS2(=O)=O)C(C(C)C)C)N)C=C1 Chemical compound FC1=CC2=C(N(C(=NS2(=O)=O)C(C(C)C)C)N)C=C1 OAQZZPXWKCHVKQ-UHFFFAOYSA-N 0.000 claims description 2
- HUGCRPORVZRUKB-UHFFFAOYSA-N FC1=CC2=C(N(C(=NS2(=O)=O)C2=CC=NC=C2)NC)C=C1 Chemical compound FC1=CC2=C(N(C(=NS2(=O)=O)C2=CC=NC=C2)NC)C=C1 HUGCRPORVZRUKB-UHFFFAOYSA-N 0.000 claims description 2
- XCRONWVJFGESQF-UHFFFAOYSA-N FC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NC)C=C1 Chemical compound FC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NC)C=C1 XCRONWVJFGESQF-UHFFFAOYSA-N 0.000 claims description 2
- VYYOGEXWDGERIL-UHFFFAOYSA-N FC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NCC)C=C1 Chemical compound FC1=CC2=C(N(C(=NS2(=O)=O)C2=NC=CC=C2)NCC)C=C1 VYYOGEXWDGERIL-UHFFFAOYSA-N 0.000 claims description 2
- CPENBVVNYGSCBF-UHFFFAOYSA-N FC1=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NC)C=C1 Chemical compound FC1=CC2=C(N(C(=NS2(=O)=O)C=2C=NC=CC2)NC)C=C1 CPENBVVNYGSCBF-UHFFFAOYSA-N 0.000 claims description 2
- NWBHTNWNVRLRMQ-SNVBAGLBSA-N IC1=CC2=C(N(C(=NS2(=O)=O)[C@H](C)C2=CC=CC=C2)N)C=C1 Chemical compound IC1=CC2=C(N(C(=NS2(=O)=O)[C@H](C)C2=CC=CC=C2)N)C=C1 NWBHTNWNVRLRMQ-SNVBAGLBSA-N 0.000 claims description 2
- RZULBBFSLZUDHS-UHFFFAOYSA-N N-cyclobutyl-7-methyl-4H-1,2,4-benzothiadiazin-3-imine Chemical compound N1SC2=CC(C)=CC=C2N=C1NC1CCC1 RZULBBFSLZUDHS-UHFFFAOYSA-N 0.000 claims description 2
- JGQXVTVHEFDJHN-UHFFFAOYSA-N N-ethyl-1,1-dioxo-4-(trifluoromethyl)-1lambda6,2,4-benzothiadiazin-3-imine Chemical compound FC(F)(F)N1C(=NS(C2=C1C=CC=C2)(=O)=O)NCC JGQXVTVHEFDJHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000001602 bicycloalkyls Chemical class 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000006114 decarboxylation reaction Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- KDHKVOMSZNKOIR-UHFFFAOYSA-N n-(2-ethylhexyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=CC=C2NC(NCC(CC)CCCC)=NS(=O)(=O)C2=C1 KDHKVOMSZNKOIR-UHFFFAOYSA-N 0.000 claims description 2
- NZOMJMJGYIAURS-UHFFFAOYSA-N n-(2-methylpropyl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=CC=C2NC(NCC(C)C)=NS(=O)(=O)C2=C1 NZOMJMJGYIAURS-UHFFFAOYSA-N 0.000 claims description 2
- MEAAIQSIBPVSDI-UHFFFAOYSA-N n-(cyclohexylmethyl)-7-iodo-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(I)=CC=C2NC=1NCC1CCCCC1 MEAAIQSIBPVSDI-UHFFFAOYSA-N 0.000 claims description 2
- LFAIZUQOYZHQMS-UHFFFAOYSA-N n-(cyclopropylmethyl)-1,1-dioxo-7-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(C(F)(F)F)=CC=C2NC=1NCC1CC1 LFAIZUQOYZHQMS-UHFFFAOYSA-N 0.000 claims description 2
- GIEJEHZIOFLVJT-UHFFFAOYSA-N n-(cyclopropylmethyl)-7-nitro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC([N+](=O)[O-])=CC=C2NC=1NCC1CC1 GIEJEHZIOFLVJT-UHFFFAOYSA-N 0.000 claims description 2
- SPOICDXSIBSZGJ-UHFFFAOYSA-N n-butan-2-yl-1,1-dioxo-7-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound FC(F)(F)C1=CC=C2NC(NC(C)CC)=NS(=O)(=O)C2=C1 SPOICDXSIBSZGJ-UHFFFAOYSA-N 0.000 claims description 2
- VKIDCKPAWLSRQE-UHFFFAOYSA-N n-butan-2-yl-6-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NC(C)CC)=NS(=O)(=O)C2=C1 VKIDCKPAWLSRQE-UHFFFAOYSA-N 0.000 claims description 2
- QZPCHMHBRKZPKT-UHFFFAOYSA-N n-butan-2-yl-7-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(NC(C)CC)=NS(=O)(=O)C2=C1 QZPCHMHBRKZPKT-UHFFFAOYSA-N 0.000 claims description 2
- OKGYFBKWGXSILA-UHFFFAOYSA-N n-butan-2-yl-7-iodo-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound IC1=CC=C2NC(NC(C)CC)=NS(=O)(=O)C2=C1 OKGYFBKWGXSILA-UHFFFAOYSA-N 0.000 claims description 2
- SXTCITAJKUDHAO-UHFFFAOYSA-N n-butan-2-yl-7-nitro-2h-1,2,4-benzothiadiazin-3-amine Chemical compound C1=C([N+]([O-])=O)C=C2SNC(NC(C)CC)=NC2=C1 SXTCITAJKUDHAO-UHFFFAOYSA-N 0.000 claims description 2
- FQBPNGZMHSYAEI-UHFFFAOYSA-N n-cyclobutyl-1,1-dioxo-6,8-bis(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C=2C(C(F)(F)F)=CC(C(F)(F)F)=CC=2NC=1NC1CCC1 FQBPNGZMHSYAEI-UHFFFAOYSA-N 0.000 claims description 2
- RZRHJKCPTHKVPD-UHFFFAOYSA-N n-cyclohexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N1C2=CC=CC=C2S(=O)(=O)N=C1NC1CCCCC1 RZRHJKCPTHKVPD-UHFFFAOYSA-N 0.000 claims description 2
- HMWNROCVRUEJHK-UHFFFAOYSA-N n-cyclohexyl-2-methyl-1,2,4-benzothiadiazin-3-amine Chemical compound CN1SC2=CC=CC=C2N=C1NC1CCCCC1 HMWNROCVRUEJHK-UHFFFAOYSA-N 0.000 claims description 2
- XCYRXPISHIMTCP-UHFFFAOYSA-N n-cyclohexyl-4-methyl-1,2,4-benzothiadiazin-3-amine Chemical compound N=1SC2=CC=CC=C2N(C)C=1NC1CCCCC1 XCYRXPISHIMTCP-UHFFFAOYSA-N 0.000 claims description 2
- AOTFRPHDIZUGEO-UHFFFAOYSA-N n-cyclohexyl-n-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC=CC=C2NC=1N(C)C1CCCCC1 AOTFRPHDIZUGEO-UHFFFAOYSA-N 0.000 claims description 2
- WOKJVIYIBIWEHR-UHFFFAOYSA-N n-cyclopentyl-6-fluoro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(F)=CC=C(S(N=2)(=O)=O)C=1NC=2NC1CCCC1 WOKJVIYIBIWEHR-UHFFFAOYSA-N 0.000 claims description 2
- REQITSDGAMSLKS-UHFFFAOYSA-N n-cyclopentyl-7-fluoro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(F)=CC=C2NC=1NC1CCCC1 REQITSDGAMSLKS-UHFFFAOYSA-N 0.000 claims description 2
- LIBKNNNYJZQNQS-UHFFFAOYSA-N n-cyclopropyl-7-fluoro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(F)=CC=C2NC=1NC1CC1 LIBKNNNYJZQNQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000003512 tertiary amines Chemical class 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- QRKDOAWSBBGNLE-UHFFFAOYSA-N 2h-1,2,4-benzothiadiazine Chemical compound C1=CC=C2N=CNSC2=C1 QRKDOAWSBBGNLE-UHFFFAOYSA-N 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 1
- FPZHNSLLHFOJMV-UHFFFAOYSA-N 5,7-dichloro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC(Cl)=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 FPZHNSLLHFOJMV-UHFFFAOYSA-N 0.000 claims 1
- IYXFBLABOZUIDN-UHFFFAOYSA-N 6,7-dichloro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=C(Cl)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 IYXFBLABOZUIDN-UHFFFAOYSA-N 0.000 claims 1
- IQQUZJCZHZVYEP-UHFFFAOYSA-N 6-chloro-n-(3-methylbutan-2-yl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NC(C)C(C)C)=NS(=O)(=O)C2=C1 IQQUZJCZHZVYEP-UHFFFAOYSA-N 0.000 claims 1
- ZBMLNHAGWNOKBE-UHFFFAOYSA-N 6-cyclohexyl-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C2NC(NC(C)C)=NS(=O)(=O)C2=CC=C1C1CCCCC1 ZBMLNHAGWNOKBE-UHFFFAOYSA-N 0.000 claims 1
- BVVSYJDCFRTBSY-UHFFFAOYSA-N 7-chloro-2-methyl-1,1-dioxo-n-propan-2-yl-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2S(=O)(=O)N(C)C(NC(C)C)=NC2=C1 BVVSYJDCFRTBSY-UHFFFAOYSA-N 0.000 claims 1
- LYKFTYOFHPPXIF-UHFFFAOYSA-N 7-chloro-2-methyl-n-(3-methylbutan-2-yl)-1,1-dioxo-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2S(=O)(=O)N(C)C(NC(C)C(C)C)=NC2=C1 LYKFTYOFHPPXIF-UHFFFAOYSA-N 0.000 claims 1
- VTRJZGRQXAQXLV-UHFFFAOYSA-N 7-chloro-n-(3-methylbutan-2-yl)-2h-1,2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2SNC(NC(C)C(C)C)=NC2=C1 VTRJZGRQXAQXLV-UHFFFAOYSA-N 0.000 claims 1
- PYEKFEYUNRUQPB-UHFFFAOYSA-N 7-chloro-n-(5-methylhexan-2-yl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(NC(C)CCC(C)C)=NS(=O)(=O)C2=C1 PYEKFEYUNRUQPB-UHFFFAOYSA-N 0.000 claims 1
- ZIRIJTDZDRLTQJ-UHFFFAOYSA-N CC(C)CCCC(C)C(N(C(C=C1)=C2C=C1Cl)N)=NS2(=O)=O Chemical compound CC(C)CCCC(C)C(N(C(C=C1)=C2C=C1Cl)N)=NS2(=O)=O ZIRIJTDZDRLTQJ-UHFFFAOYSA-N 0.000 claims 1
- YRODFTJCOMCDHY-UHFFFAOYSA-N CCC(C)CC(C)C(N(C(C=C1)=C2C=C1Cl)N)=NS2(=O)=O Chemical compound CCC(C)CC(C)C(N(C(C=C1)=C2C=C1Cl)N)=NS2(=O)=O YRODFTJCOMCDHY-UHFFFAOYSA-N 0.000 claims 1
- 235000014676 Phragmites communis Nutrition 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- IMJGTPNJEXRCIU-UHFFFAOYSA-N n-cyclohexyl-6-(trifluoromethyl)-2h-1,2,4-benzothiadiazin-3-amine Chemical compound N=1C2=CC(C(F)(F)F)=CC=C2SNC=1NC1CCCCC1 IMJGTPNJEXRCIU-UHFFFAOYSA-N 0.000 claims 1
- UPRHPDRXDVNVER-UHFFFAOYSA-N n-cyclopropyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N1C2=CC=CC=C2S(=O)(=O)N=C1NC1CC1 UPRHPDRXDVNVER-UHFFFAOYSA-N 0.000 claims 1
- KCJNVDXEURIDOL-UHFFFAOYSA-N n-ethyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=CC=C2NC(NCC)=NS(=O)(=O)C2=C1 KCJNVDXEURIDOL-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 12
- 210000003169 central nervous system Anatomy 0.000 abstract description 7
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 2
- 210000000750 endocrine system Anatomy 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 230000002685 pulmonary effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 238000001914 filtration Methods 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- 239000002244 precipitate Substances 0.000 description 27
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- VHBFEIBMZHEWSX-UHFFFAOYSA-N 2-isothiocyanatopropane Chemical compound CC(C)N=C=S VHBFEIBMZHEWSX-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 238000006798 ring closing metathesis reaction Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000004821 distillation Methods 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 229940127315 Potassium Channel Openers Drugs 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000007429 general method Methods 0.000 description 7
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 7
- 150000002540 isothiocyanates Chemical class 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 150000004693 imidazolium salts Chemical class 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229930195734 saturated hydrocarbon Natural products 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- PDXCOWCINSIDPO-UHFFFAOYSA-N 2h-thiadiazine 1,1-dioxide Chemical compound O=S1(=O)NN=CC=C1 PDXCOWCINSIDPO-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 150000003973 alkyl amines Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- GDLBFKVLRPITMI-UHFFFAOYSA-N diazoxide Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000004682 monohydrates Chemical class 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 4
- HWQDHHCUOZZFIG-UHFFFAOYSA-N 2-amino-4-chlorobenzenesulfonamide Chemical compound NC1=CC(Cl)=CC=C1S(N)(=O)=O HWQDHHCUOZZFIG-UHFFFAOYSA-N 0.000 description 3
- UOCUSOBVEHOMMB-UHFFFAOYSA-N 2h-1$l^{6},2,3-benzothiadiazine 1,1-dioxide Chemical class C1=CC=C2S(=O)(=O)NN=CC2=C1 UOCUSOBVEHOMMB-UHFFFAOYSA-N 0.000 description 3
- YHOBVYWCMLSCRQ-UHFFFAOYSA-N 3-imidazol-1-yl-2H-1,2,4-benzothiadiazine-7-carboxylic acid Chemical compound N1SC2=CC(C(=O)O)=CC=C2N=C1N1C=CN=C1 YHOBVYWCMLSCRQ-UHFFFAOYSA-N 0.000 description 3
- JOZZAIIGWFLONA-UHFFFAOYSA-N 3-methylbutan-2-amine Chemical compound CC(C)C(C)N JOZZAIIGWFLONA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 206010047163 Vasospasm Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 229960004042 diazoxide Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- POXAIQSXNOEQGM-UHFFFAOYSA-N propan-2-ylthiourea Chemical compound CC(C)NC(N)=S POXAIQSXNOEQGM-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- OSOUNOBYRMOXQQ-UHFFFAOYSA-N 1-chloro-3-methylbenzene Chemical compound CC1=CC=CC(Cl)=C1 OSOUNOBYRMOXQQ-UHFFFAOYSA-N 0.000 description 2
- WJVMARQNXIKFPI-UHFFFAOYSA-N 2-amino-4,5-dichlorobenzenesulfonamide Chemical compound NC1=CC(Cl)=C(Cl)C=C1S(N)(=O)=O WJVMARQNXIKFPI-UHFFFAOYSA-N 0.000 description 2
- CEIMELGOEGZARD-UHFFFAOYSA-N 2-amino-4,6-dichlorobenzenesulfonamide Chemical compound NC1=CC(Cl)=CC(Cl)=C1S(N)(=O)=O CEIMELGOEGZARD-UHFFFAOYSA-N 0.000 description 2
- DDCSIAAOAFIZPP-UHFFFAOYSA-N 2-amino-4-fluorobenzenesulfonamide Chemical compound NC1=CC(F)=CC=C1S(N)(=O)=O DDCSIAAOAFIZPP-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- ZAJALNCZCSSGJC-UHFFFAOYSA-N 2-chloro-5-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC([N+]([O-])=O)=CC=C1Cl ZAJALNCZCSSGJC-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- DXSUORGKJZADET-UHFFFAOYSA-N 3,3-dimethylbutan-2-amine Chemical compound CC(N)C(C)(C)C DXSUORGKJZADET-UHFFFAOYSA-N 0.000 description 2
- QAZOMTIGEPQLEG-UHFFFAOYSA-N 3,7-dichloro-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C(Cl)C=C2S(=O)(=O)NC(Cl)=NC2=C1 QAZOMTIGEPQLEG-UHFFFAOYSA-N 0.000 description 2
- RBOBXILUTBVQOQ-UHFFFAOYSA-N 3-methylbutan-2-ylazanium;chloride Chemical compound Cl.CC(C)C(C)N RBOBXILUTBVQOQ-UHFFFAOYSA-N 0.000 description 2
- HZOMHQLECOWBSX-UHFFFAOYSA-N 4-amino-3-sulfamoylbenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1S(N)(=O)=O HZOMHQLECOWBSX-UHFFFAOYSA-N 0.000 description 2
- APTCTOIXXMWJRV-UHFFFAOYSA-N 6-chloro-n-octyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NCCCCCCCC)=NS(=O)(=O)C2=C1 APTCTOIXXMWJRV-UHFFFAOYSA-N 0.000 description 2
- FMMDYVAEIOJPRK-UHFFFAOYSA-N 7-bromo-n-butan-2-yl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound BrC1=CC=C2NC(NC(C)CC)=NS(=O)(=O)C2=C1 FMMDYVAEIOJPRK-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- CAUWMJAWTZHJTG-UHFFFAOYSA-N C1(=NS(=O)(=O)C2=C(N1)C=CC(=C2)I)N Chemical compound C1(=NS(=O)(=O)C2=C(N1)C=CC(=C2)I)N CAUWMJAWTZHJTG-UHFFFAOYSA-N 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000927721 Tritia Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000005605 benzo group Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- HBNYJWAFDZLWRS-UHFFFAOYSA-N ethyl isothiocyanate Chemical compound CCN=C=S HBNYJWAFDZLWRS-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IZJDOKYDEWTZSO-UHFFFAOYSA-N phenethyl isothiocyanate Chemical compound S=C=NCCC1=CC=CC=C1 IZJDOKYDEWTZSO-UHFFFAOYSA-N 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000004036 potassium channel stimulating agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JUOBCZMEQHUKSA-UHFFFAOYSA-N 1,1-dioxo-3-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazine-3,7-diamine Chemical compound NC1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 JUOBCZMEQHUKSA-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- SANCAOWRHRUCMY-UHFFFAOYSA-N 1-(2-amino-4-propan-2-ylphenyl)sulfonyl-3-propan-2-ylthiourea Chemical compound CC(C)NC(=S)NS(=O)(=O)C1=CC=C(C(C)C)C=C1N SANCAOWRHRUCMY-UHFFFAOYSA-N 0.000 description 1
- OORVFLLZGHCBDX-UHFFFAOYSA-N 1-(2-amino-5-tert-butylphenyl)sulfonyl-3-propan-2-ylthiourea Chemical compound CC(C)NC(=S)NS(=O)(=O)C1=CC(C(C)(C)C)=CC=C1N OORVFLLZGHCBDX-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- KKASGUHLXWAKEZ-UHFFFAOYSA-N 1-isothiocyanatopropane Chemical compound CCCN=C=S KKASGUHLXWAKEZ-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000006135 2,2-dimethylpropyl sulfonyl group Chemical group 0.000 description 1
- FEJCSYUIRWSKNZ-UHFFFAOYSA-N 2-(benzylamino)-5-(trifluoromethyl)benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1NCC1=CC=CC=C1 FEJCSYUIRWSKNZ-UHFFFAOYSA-N 0.000 description 1
- VJKYXVOXPDJXFO-UHFFFAOYSA-N 2-[1,1-dioxo-3-(propan-2-ylamino)-4h-1$l^{6},2,4-benzothiadiazin-6-yl]acetamide Chemical compound C1=C(CC(N)=O)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 VJKYXVOXPDJXFO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DQNCVHIKQIPEIA-UHFFFAOYSA-N 2-amino-3,5-dibromobenzenesulfonamide Chemical compound NC1=C(Br)C=C(Br)C=C1S(N)(=O)=O DQNCVHIKQIPEIA-UHFFFAOYSA-N 0.000 description 1
- MPCVBXMJCJCRPF-UHFFFAOYSA-N 2-amino-3,5-dichlorobenzenesulfonamide Chemical compound NC1=C(Cl)C=C(Cl)C=C1S(N)(=O)=O MPCVBXMJCJCRPF-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- WCZMLHOUKYCJLD-UHFFFAOYSA-N 2-amino-4-(benzenesulfonyl)benzenesulfonamide Chemical compound C1=C(S(N)(=O)=O)C(N)=CC(S(=O)(=O)C=2C=CC=CC=2)=C1 WCZMLHOUKYCJLD-UHFFFAOYSA-N 0.000 description 1
- CTXATGRVXHPTHR-UHFFFAOYSA-N 2-amino-4-(trifluoromethyl)benzenesulfonamide Chemical compound NC1=CC(C(F)(F)F)=CC=C1S(N)(=O)=O CTXATGRVXHPTHR-UHFFFAOYSA-N 0.000 description 1
- YTMRKTDZUYMLPK-UHFFFAOYSA-N 2-amino-4-chloro-5-fluorobenzenesulfonamide Chemical compound NC1=CC(Cl)=C(F)C=C1S(N)(=O)=O YTMRKTDZUYMLPK-UHFFFAOYSA-N 0.000 description 1
- BCMHJYATXMPGPN-UHFFFAOYSA-N 2-amino-4-hexylbenzenesulfonamide Chemical compound CCCCCCC1=CC=C(S(N)(=O)=O)C(N)=C1 BCMHJYATXMPGPN-UHFFFAOYSA-N 0.000 description 1
- NECSZWFYSDDJSW-UHFFFAOYSA-N 2-amino-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C(N)=C1 NECSZWFYSDDJSW-UHFFFAOYSA-N 0.000 description 1
- BBBWGBCKRRVGAY-UHFFFAOYSA-N 2-amino-4-phenoxybenzenesulfonamide Chemical compound C1=C(S(N)(=O)=O)C(N)=CC(OC=2C=CC=CC=2)=C1 BBBWGBCKRRVGAY-UHFFFAOYSA-N 0.000 description 1
- BGILQOXCWMHWOM-UHFFFAOYSA-N 2-amino-5-bromobenzenesulfonamide Chemical compound NC1=CC=C(Br)C=C1S(N)(=O)=O BGILQOXCWMHWOM-UHFFFAOYSA-N 0.000 description 1
- XNQOPGBCDOJUPL-UHFFFAOYSA-N 2-amino-5-chloro-3-nitrobenzenesulfonamide Chemical compound NC1=C([N+]([O-])=O)C=C(Cl)C=C1S(N)(=O)=O XNQOPGBCDOJUPL-UHFFFAOYSA-N 0.000 description 1
- RBCLOSOKWLMKMB-UHFFFAOYSA-N 2-amino-5-chlorobenzenesulfonamide Chemical compound NC1=CC=C(Cl)C=C1S(N)(=O)=O RBCLOSOKWLMKMB-UHFFFAOYSA-N 0.000 description 1
- TZPOFKNGJJYOPZ-UHFFFAOYSA-N 2-amino-5-iodobenzenesulfonamide Chemical compound NC1=CC=C(I)C=C1S(N)(=O)=O TZPOFKNGJJYOPZ-UHFFFAOYSA-N 0.000 description 1
- GKTVIFGJASUBGA-UHFFFAOYSA-N 2-amino-5-methylbenzenesulfonamide Chemical compound CC1=CC=C(N)C(S(N)(=O)=O)=C1 GKTVIFGJASUBGA-UHFFFAOYSA-N 0.000 description 1
- SKATTZSUUSDLRS-UHFFFAOYSA-N 2-amino-5-nitrobenzenesulfonamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1S(N)(=O)=O SKATTZSUUSDLRS-UHFFFAOYSA-N 0.000 description 1
- WSODCXJOVXHDSZ-UHFFFAOYSA-N 2-amino-5-tert-butylbenzenesulfonamide Chemical compound CC(C)(C)C1=CC=C(N)C(S(N)(=O)=O)=C1 WSODCXJOVXHDSZ-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- KWIXNFOTNVKIGM-UHFFFAOYSA-N 2-chloro-5-nitroaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1Cl KWIXNFOTNVKIGM-UHFFFAOYSA-N 0.000 description 1
- TUFJIDJGIQOYFY-UHFFFAOYSA-N 2-isothiocyanatobutane Chemical compound CCC(C)N=C=S TUFJIDJGIQOYFY-UHFFFAOYSA-N 0.000 description 1
- MQBVMZMUVGRESP-UHFFFAOYSA-N 2-methyl-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)N(C)C=NC2=C1 MQBVMZMUVGRESP-UHFFFAOYSA-N 0.000 description 1
- SCYJOXBJQVTSSQ-UHFFFAOYSA-N 2-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-one Chemical compound C1=CC=C2S(=O)(=O)N(C)C(=O)NC2=C1 SCYJOXBJQVTSSQ-UHFFFAOYSA-N 0.000 description 1
- VJROPLWGFCORRM-UHFFFAOYSA-N 2-methylbutan-1-amine Chemical compound CCC(C)CN VJROPLWGFCORRM-UHFFFAOYSA-N 0.000 description 1
- 125000006131 2-methylbutyl sulfonyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000005979 2-naphthyloxy group Chemical group 0.000 description 1
- 125000004135 2-norbornyl group Chemical group [H]C1([H])C([H])([H])C2([H])C([H])([H])C1([H])C([H])([H])C2([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical compound C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical class NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- YXMYAEDUYDSZOK-UHFFFAOYSA-N 3,7-dichloro-2h-1,2,4-benzothiadiazine Chemical compound C1=C(Cl)C=C2SNC(Cl)=NC2=C1 YXMYAEDUYDSZOK-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AXCMTSWJZUVRFV-UHFFFAOYSA-N 3-imidazol-1-yl-7-nitro-2H-1,2,4-benzothiadiazine Chemical compound N1SC2=CC([N+](=O)[O-])=CC=C2N=C1N1C=CN=C1 AXCMTSWJZUVRFV-UHFFFAOYSA-N 0.000 description 1
- KGRMFBDVQFPNCA-UHFFFAOYSA-N 3-imidazol-1-yl-7-nitro-4H-1lambda6,2,4-benzothiadiazine 1,1-dioxide Chemical compound N=1S(=O)(=O)C2=CC([N+](=O)[O-])=CC=C2NC=1N1C=CN=C1 KGRMFBDVQFPNCA-UHFFFAOYSA-N 0.000 description 1
- 125000006132 3-methylbutyl sulfonyl group Chemical group 0.000 description 1
- RFDABPDQNQBOJV-UHFFFAOYSA-N 3-methylsulfanyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical class C1=CC=C2S(=O)(=O)NC(SC)=NC2=C1 RFDABPDQNQBOJV-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CXRHVZBYOMPUPP-UHFFFAOYSA-N 4-acetyl-2-aminobenzenesulfonamide Chemical compound CC(=O)C1=CC=C(S(N)(=O)=O)C(N)=C1 CXRHVZBYOMPUPP-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- 125000006141 4-methylpentyl sulfonyl group Chemical group 0.000 description 1
- AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- IZCBXLKODYZSDJ-UHFFFAOYSA-N 5-methylhexan-2-amine Chemical compound CC(C)CCC(C)N IZCBXLKODYZSDJ-UHFFFAOYSA-N 0.000 description 1
- FEMWGGYXOKPKQW-UHFFFAOYSA-N 6,7-dichloro-3-imidazol-1-yl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide;hydrate Chemical compound O.N=1S(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2NC=1N1C=CN=C1 FEMWGGYXOKPKQW-UHFFFAOYSA-N 0.000 description 1
- YKIURJRJQMZMBF-UHFFFAOYSA-N 6,7-dichloro-n-(3-methylbutan-2-yl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=C(Cl)C=C2NC(NC(C)C(C)C)=NS(=O)(=O)C2=C1 YKIURJRJQMZMBF-UHFFFAOYSA-N 0.000 description 1
- KGVQOCNDRJLOMD-UHFFFAOYSA-N 6,7-dichloro-n-hexyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=C(Cl)C=C2NC(NCCCCCC)=NS(=O)(=O)C2=C1 KGVQOCNDRJLOMD-UHFFFAOYSA-N 0.000 description 1
- CLWJBTNSDQIMNT-UHFFFAOYSA-N 6-chloro-1,1,3-trioxo-4h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(=O)NS2(=O)=O CLWJBTNSDQIMNT-UHFFFAOYSA-N 0.000 description 1
- LECQMVQKPLRRDZ-UHFFFAOYSA-N 6-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-one Chemical class N1C(=O)NS(=O)(=O)C=2C1=CC(Cl)=CC=2 LECQMVQKPLRRDZ-UHFFFAOYSA-N 0.000 description 1
- KIHRZGGELDFPPA-UHFFFAOYSA-N 6-chloro-3-(3-methylbutan-2-ylamino)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(NC(C)C(C)C)=NS(=O)(=O)C2=C1 KIHRZGGELDFPPA-UHFFFAOYSA-N 0.000 description 1
- HCWVFJOPFAHTEO-UHFFFAOYSA-N 6-chloro-4H-1,2,4-benzothiadiazin-3-one Chemical compound S1NC(=O)NC2=CC(Cl)=CC=C21 HCWVFJOPFAHTEO-UHFFFAOYSA-N 0.000 description 1
- AETOKTHGOLBNQY-UHFFFAOYSA-N 6-chloro-n-cyclobutyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(Cl)=CC=C(S(N=2)(=O)=O)C=1NC=2NC1CCC1 AETOKTHGOLBNQY-UHFFFAOYSA-N 0.000 description 1
- SZZXOTUIAQWEAT-UHFFFAOYSA-N 7-bromo-1,1-dioxo-n-propan-2-yl-6-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound BrC1=C(C(F)(F)F)C=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 SZZXOTUIAQWEAT-UHFFFAOYSA-N 0.000 description 1
- SPGQQKFASWEDGN-UHFFFAOYSA-N 7-chloro-4-methyl-1,1-dioxo-n-propan-2-yl-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2N(C)C(NC(C)C)=NS(=O)(=O)C2=C1 SPGQQKFASWEDGN-UHFFFAOYSA-N 0.000 description 1
- YCORWOKIDPQHKY-UHFFFAOYSA-N 7-chloro-n-(3-methylbutan-2-yl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(NC(C)C(C)C)=NS(=O)(=O)C2=C1 YCORWOKIDPQHKY-UHFFFAOYSA-N 0.000 description 1
- GSWCUPSEPULYMM-UHFFFAOYSA-N 7-chloro-n-(6-methylheptan-2-yl)-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound ClC1=CC=C2NC(NC(C)CCCC(C)C)=NS(=O)(=O)C2=C1 GSWCUPSEPULYMM-UHFFFAOYSA-N 0.000 description 1
- KFNWDGMCTOKMHH-UHFFFAOYSA-N 7-chloro-n-cyclobutyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(Cl)=CC=C2NC=1NC1CCC1 KFNWDGMCTOKMHH-UHFFFAOYSA-N 0.000 description 1
- UWXTUHPDDVZCAK-UHFFFAOYSA-N 7-iodo-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound IC1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 UWXTUHPDDVZCAK-UHFFFAOYSA-N 0.000 description 1
- HLSLMVMGOSTMGA-UHFFFAOYSA-N 7-methoxy-1,1-dioxo-n-propyl-4h-1$l^{6},2,4-benzothiadiazin-3-amine;hydrate Chemical compound O.COC1=CC=C2NC(NCCC)=NS(=O)(=O)C2=C1 HLSLMVMGOSTMGA-UHFFFAOYSA-N 0.000 description 1
- GQWCPMREPBODKI-UHFFFAOYSA-N 7-methyl-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound CC1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 GQWCPMREPBODKI-UHFFFAOYSA-N 0.000 description 1
- ZAXLSGVPIBYHTD-UHFFFAOYSA-N 7-nitro-1,1-dioxo-n-propan-2-yl-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound [O-][N+](=O)C1=CC=C2NC(NC(C)C)=NS(=O)(=O)C2=C1 ZAXLSGVPIBYHTD-UHFFFAOYSA-N 0.000 description 1
- 125000004136 7-norbornyl group Chemical group [H]C1([H])C([H])([H])C2([H])C([H])([H])C([H])([H])C1([H])C2([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ADDPPUZSEGQFQZ-UHFFFAOYSA-N C1=CC2=C(C=C1Cl)S(=O)(=O)N=C(N2N)C3=CC=NC=C3 Chemical compound C1=CC2=C(C=C1Cl)S(=O)(=O)N=C(N2N)C3=CC=NC=C3 ADDPPUZSEGQFQZ-UHFFFAOYSA-N 0.000 description 1
- PVUHLNPVPKZVCH-UHFFFAOYSA-N CC(C)C(C)C(N1C)=NC(C(N)=CC(Cl)=C2)=C2S1(=O)=O Chemical compound CC(C)C(C)C(N1C)=NC(C(N)=CC(Cl)=C2)=C2S1(=O)=O PVUHLNPVPKZVCH-UHFFFAOYSA-N 0.000 description 1
- FYUUCDISMAZYAU-UHFFFAOYSA-N CC(CC)C1=NS(C2=C(N1N)C=CC(=C2)F)(=O)=O Chemical compound CC(CC)C1=NS(C2=C(N1N)C=CC(=C2)F)(=O)=O FYUUCDISMAZYAU-UHFFFAOYSA-N 0.000 description 1
- KGZSANQRIRWICF-UHFFFAOYSA-N CC(COC)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl Chemical compound CC(COC)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)Cl KGZSANQRIRWICF-UHFFFAOYSA-N 0.000 description 1
- PZFVMWPLAUTEPX-UHFFFAOYSA-N CC(COC)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)F Chemical compound CC(COC)C1=NS(=O)(=O)C2=C(N1N)C=CC(=C2)F PZFVMWPLAUTEPX-UHFFFAOYSA-N 0.000 description 1
- AFMGXEVZEYAXHV-UHFFFAOYSA-N CCNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=NC=C3 Chemical compound CCNN1C2=C(C(=CC(=C2)Cl)Cl)S(=O)(=O)N=C1C3=CC=NC=C3 AFMGXEVZEYAXHV-UHFFFAOYSA-N 0.000 description 1
- VAJJVUQVKFRKJW-UHFFFAOYSA-N CCNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=NC=C3 Chemical compound CCNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CC=NC=C3 VAJJVUQVKFRKJW-UHFFFAOYSA-N 0.000 description 1
- PALIMYDNZPZKOC-UHFFFAOYSA-N CCNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CN=CC=C3 Chemical compound CCNN1C2=C(C(=CC(=C2)F)F)S(=O)(=O)N=C1C3=CN=CC=C3 PALIMYDNZPZKOC-UHFFFAOYSA-N 0.000 description 1
- NRGMBBAMRJHKAH-UHFFFAOYSA-N CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=CC=N3)F)F Chemical compound CNN1C2=CC(=C(C=C2S(=O)(=O)N=C1C3=CC=CC=N3)F)F NRGMBBAMRJHKAH-UHFFFAOYSA-N 0.000 description 1
- NWBHTNWNVRLRMQ-JTQLQIEISA-N C[C@@H](C1=CC=CC=C1)C2=NS(=O)(=O)C3=C(N2N)C=CC(=C3)I Chemical compound C[C@@H](C1=CC=CC=C1)C2=NS(=O)(=O)C3=C(N2N)C=CC(=C3)I NWBHTNWNVRLRMQ-JTQLQIEISA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RTYUANYUPNYWFD-UHFFFAOYSA-N ClC(C=C1)=CC2=C1NC=N[S+]2N(CC1=CC=CC=C1)C1CNCC1 Chemical compound ClC(C=C1)=CC2=C1NC=N[S+]2N(CC1=CC=CC=C1)C1CNCC1 RTYUANYUPNYWFD-UHFFFAOYSA-N 0.000 description 1
- AIBZFUJJGYUVRY-UHFFFAOYSA-N ClC1=CC2=C(N(C(=NS2(=O)=O)CC2CCCCC2)N)C=C1 Chemical compound ClC1=CC2=C(N(C(=NS2(=O)=O)CC2CCCCC2)N)C=C1 AIBZFUJJGYUVRY-UHFFFAOYSA-N 0.000 description 1
- AMCBRHJPRYZZDV-UHFFFAOYSA-N ClC=1C=CC2=C(N(C(=NS2(=O)=O)C(CCCC(C)C)C)N)C1 Chemical compound ClC=1C=CC2=C(N(C(=NS2(=O)=O)C(CCCC(C)C)C)N)C1 AMCBRHJPRYZZDV-UHFFFAOYSA-N 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- YENKVSFFDWSKER-UHFFFAOYSA-N FC=1C=C(N)C=CC1F.NC1=C(C=C(C(=C1)F)F)S(=O)(=O)N Chemical compound FC=1C=C(N)C=CC1F.NC1=C(C=C(C(=C1)F)F)S(=O)(=O)N YENKVSFFDWSKER-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- SVYKKECYCPFKGB-UHFFFAOYSA-N N,N-dimethylcyclohexylamine Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- HPATUFMQVYVDNK-UHFFFAOYSA-N NCCC1=NS(C2=C(N1N)C=CC(=C2)Cl)(=O)=O Chemical compound NCCC1=NS(C2=C(N1N)C=CC(=C2)Cl)(=O)=O HPATUFMQVYVDNK-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- YHYHRFICQWDJNZ-UHFFFAOYSA-N azanium ethanimidate Chemical compound N.CC(N)=O YHYHRFICQWDJNZ-UHFFFAOYSA-N 0.000 description 1
- ZFSFDELZPURLKD-UHFFFAOYSA-N azanium;hydroxide;hydrate Chemical compound N.O.O ZFSFDELZPURLKD-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940090012 bentyl Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- ZIQIQOUPRHPOIT-UHFFFAOYSA-N cyclobutylazanide Chemical compound [NH-]C1CCC1 ZIQIQOUPRHPOIT-UHFFFAOYSA-N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical group [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006262 isopropyl amino sulfonyl group Chemical group 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- DZMSMSCEWOYONI-UHFFFAOYSA-N n-(3-methylbutan-2-yl)-7-nitro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound [O-][N+](=O)C1=CC=C2NC(NC(C)C(C)C)=NS(=O)(=O)C2=C1 DZMSMSCEWOYONI-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
- UHSOGNWPYNHEBY-UHFFFAOYSA-N n-cyclobutyl-7-methyl-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound N=1S(=O)(=O)C2=CC(C)=CC=C2NC=1NC1CCC1 UHSOGNWPYNHEBY-UHFFFAOYSA-N 0.000 description 1
- KTXIQLWYGSJHTH-UHFFFAOYSA-N n-cyclohexyl-1,1-dioxo-6-(trifluoromethyl)-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C=1C(C(F)(F)F)=CC=C(S(N=2)(=O)=O)C=1NC=2NC1CCCCC1 KTXIQLWYGSJHTH-UHFFFAOYSA-N 0.000 description 1
- 125000006137 n-hexyl sulfonyl group Chemical group 0.000 description 1
- 125000006129 n-pentyl sulfonyl group Chemical group 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
- VEGXHLIWGAMLEK-UHFFFAOYSA-N n-tert-butyl-6-chloro-1,1-dioxo-4h-1$l^{6},2,4-benzothiadiazin-3-amine Chemical compound C1=C(Cl)C=C2NC(NC(C)(C)C)=NS(=O)(=O)C2=C1 VEGXHLIWGAMLEK-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- AAQLCVOBBOXZOR-UHFFFAOYSA-N pyridazin-3-yl acetate Chemical compound CC(=O)OC1=CC=CN=N1 AAQLCVOBBOXZOR-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000009943 skeletal muscle blood flow Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 238000011684 zucker rat (obese) Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記一般式Iの化合物、その薬学的に許容可能な酸または塩基との塩、何 れかの光学異性体もしくはラセミ混合物を含む光学異性体の混合物、または互変 異性体 ここで、 R1およびR5は独立に、水素;ヒドロキシ;C1-6-アルコキシ;C1-6-アルキル ,ハロゲン,ヒドロキシもしくはC1-6-アルコキシで任意にモノ置換もしくはポ リ置換されたC3-6-シクロアルキル;または任意にハロゲンでモノ置換もしくは ポリ置換されたC1-6-アルキル,C2-6-アルケニルもしくはC2-6-アルキニルで あり、且つR1は水素であるか;或いは、 R1はR5と一緒になって、式Iにおける原子2と原子3との間の二重結合の一 つの結合を表し、且つR1は上記で定義した通りであるか;或いは、 R4はR1と一緒にになって、式Iにおける原子3と原子4との間の二重結合の 一つの結合を表し、且つR5は上記で定義した通りであり; Dは-S(=O)2-または-S(=O)-を表し; R2は水素;ヒドロキシ;C1-6-アルコキシ;C1-6-アルキル,ハロゲン,ヒドロ キシもしくはC1-6-アルコキシで任意に置換されたC3-6-シクロアルキル;また は任意にハロゲンでモノ置換もしくはポリ置換されたC1-6-アルキル,C2-6-ア ルケニルもしくはC2-6-アルキニルであり; R3は、R8;-OR8;-C(=X1)R8;ハロゲン,ヒドロキシ,C1-6-アルキル,C1 -6 -アルコキシ,アリーロキシ,アリールアルコキシ,ニトロ,アミノ,C1-6-モノ アルキル-もしくはジアルキルアミノ,シアノ,オキソ,アシルもしくはC1-6- アルコキシカルボニルで 任意にモノ置換もしくはポリ置換された、ビシクロアルキル,アリール,ヘテロ アリール,アリールアルキルもしくはヘテロアリールアルキルであり; R8は水素;C3-6-シクロアルキルもしくは(C3-6-シクロアルキル)C1-8-アル キル[該C3-6-シクロアルキル基は任意に、C1-6-アルキル,ハロゲン,ヒドロ キシもしくはC1-6-アルコキシでモノ置換もしくはポリ置換されていてもよい] ;1以上の窒素原子、酸素原子もしくは疏黄原子を有する飽和の3〜6員環系[任 意に、ハロゲン,シアノ,トリフルオロメチル,C1-6-アルキル,C1-6-alkoxy, C1-6-アルコキシ-C1-6アルキル,アリール,アリールアルキル,ヒドロキシ, オキソ,ニトロ,アミノ, C1-6-モノアルキルもしくはジアルキルアミノでモ ノ置換もしくはポリ置換される];または直鎖もしくは分岐鎖のC1-18-アルキ ル[任意に、ハロゲン,ヒドロキシ,C1-6-アルコキシ,C1-6-アルキルチオ,C3 -6 -シクロアルキル,アリール,アリーロキシ,アリールアルコキシ,ニトロ, アミノ,C1-6-モノアルキルもしくはジアルキルアミノ,シアノ,オキソ,ホル ミル,アシル,カルボキシ,C1-6-アルコキシカルボニル,カルバモイル,ホル ミルアミノ,またはC1-6-アルキルカルボニルアミノで置換される]; X1は、OまたはSであり; R3は、 であり[ここで、n,m,pは独立して0,1,2,3であり、またR10は水素;ヒドロキシ; C1-6-アルコキシ;C3-8-シクロアルキル(任意に、C1-6-アルキル,ハロゲン ,ヒドロキシもしくはC1-6アルコキシでモノ置換もしくはポリ置換される); または任意にハロゲンでモノ置換もしくはポリ置換されたC1-6-アルキル,C2-6 -アルケニルもしくはC2-6-アルキニルである]; R12,R13,R14,R15は独立に、水素;ハロゲン;C1-18-アルキル;C3-6-シク ロアルキル;ヒドロキシ;C1-6-アルコキシ;C1-6-アルコキシ-C1-6-アルキル; ニトロ;アミノ;シア ノ;シアノメチル;ペルハロメチル;C1-6モノアルキル-もしくはジアルキルアミ ノ;スルファモイル;C1-6-アルキルチオ;C1-6-アルキルスルホニル;C1-6-アル キルスルフィニル;C1-6-アルキルカルボニルアミノ;ホルミル;アリールチオ, アリールスルフィニル,アリールスルホニル[ここで、アリール基は任意にC1- 6 -アルキル,ハロゲン,ヒヒドロキシもしくはC1-6-アルコキシでモノ置換もし くはポリ置換される];C1-6-アルコキシカルボニル;C1-6-アルコキシカルボニ ル-C1-6-アルキル;カルバミル;カルバミルメチル;C1-6-モノアルキル-もしく はジアルモルアミノカルボニル;C1-6-モノアルキル-もしくはジアルキルアミノ チオカルボニル;ウレイド;C1-6-モノアルキル-もしくはジアルキルアミノカル ボニルアミノ,チオウレイド;C1-6-モノアルキル-もしくはジアルキルアミノチ オ-カルボニルアミノ;C1-6-モノアルキル-もしくはジアルキルアミノスルホニ ル;カルボキシ;カルボキシ-C1-6-アルキル;アシル;アリール,アリールアルキ ル,アリーロキシ[これらアリール基は任意に、C1-6-アルキル,ハロゲン ヒ ドロキシもしくはC1-6-アルコキシでモノ置換もしくはポリ置換される];(1,2, 4-オキサジアゾール-5-イル)-もしくは(1,2,4-オキサジアゾール-3-イル)-C1-6 アルキル[このオキサジアゾリル基は任意に、C1-6-アルキルもしくはC3-6-シ クロアルキルで置換される];または窒素を含む5-6員環[任意にフェニルもしく はC1-6-アルキルで置換される]である。 2.詰求項1に記載の化合物でめって、R1およびR5のうちの一つは水素;ヒ ドロキシ;C1-6-アルコキシ;C3-6-シクロアルキル[任意にC1-6-アルキル,ハ ロゲン,ヒドロキシもしくはC1-6アルコキシでモノ置換もしくはポリ置換され る];任意にハロゲンでモノ置換もしくはポリ置換される、C1-6-アルキル,C1-6 アルケニルもしくはC2-6-アルキニルであり;R1およびR5の他方はR4と共に 結合である化合物。 3.請求項1または2に記載の化合物であって、DはS(=O)2-を表す化合物 。 4.請求項1〜3の何れか1項に記載の化合物であって、R2は水素もしくは C1-6-アルキルである化合物。 5.請求項1〜4の何れか1項に記載の化合物であって、R2が水素である化 合物 6.請求項1〜5の何れか1項に記載の化合物であって、R3はR8;-OR8;- C(=O)R8であり、ここでR8は水素;C3-6-シクロアルキルまたは(C3-6-シク ロアルキル)C1-6-アルキル,任意にC1-6アルキル,ハロゲン,ヒドロキシもし くはC1-6-アルコキシでモノ置換もしくはポリ置換されたC3-6-シクロアルキル ;1以上の窒素原子、酸素原子または硫黄原子を含む飽和3-6員環;または圧意に ハロゲン,C3-6-シクロアルキル,ヒドロキシもしくはC1-6アルコキシで置換さ れた直鎖または分岐鎖のC1-18-アルキルである化合物。 7.請求項1〜6の何れか1項に記載の化合物であって、R3は、任意にC1-6 -アルキル,ハロゲン,ヒドロキシもしくはC1-6-アルコキシでモノ置換もしく はポリ置換された二級C3-8-アルキル,三級C4-6-アルキル,C3-6-シクロアル キルまたは(C3-6-シクロアルキル)メチルである化合物。 8.請求項1〜7の何れか1項に記載の化合物であって、R12,R13,R14,R1 5 は独立にハロゲンである化合物。 9.請求項1〜8の何れか1項に記載の化合物であって、R13はハロゲンであ る化合物。 10.請求項1に記載の化合物であって、下記の中から選ばれる化合物: ・3-ベンジロキシアミノ-7-クロロ-4H-1,2,4-ベンゾチアジアジン1.1-ジオキシ ド ・7-クロロ-3-メトキシアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-ブロモ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-クロロ-3-(N-エチル-N-メチルアミノ)-4H-1,2,4-ベンゾチアジアジン1.1 -ジオキシド ・6-クロロ-3-メトキシアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-クロロ-3-(1,2,2-トリメチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・7-ブロモ-3-(1,2,2-トリメチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・6-クロロ-3-(N-エチル-N-メチルアミノ)-4H-1,2,4-ベンゾチアジアジン1,1 -ジオキ シド ・5-アミノ-7-クロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1 -ジオキシド ・7-クロロ-3-(1.3-ジメチルペンチル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-クロロ-3-(1.5-ジメチルヘキシル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-クロロ-3-(1,4-ジメチルペンチル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオ キシド ・5,7-ジクロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・7-ブロモ-6-トリフルオロメチル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチ アジアジン1,1-ジオキシド ・7-クロロ-3-(3,3-ジフェニルプロピルアミノ)-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・7-クロロ-3-(4-フェニルブチルアミノ)-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(3-ジエチルアミノ-1-メチルプロピルアミノ)-4H-1,2,4-ベンゾ チアジアジン1,1-ジオキシド ・3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン-5-カルボキシアルデヒ ド1,1-ジオキシド ・3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン-7-カルボキシアルデヒ ド1,1-ジオキシド ・3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン-6-カルボン酸1.1-ジオ キシド ・7-シアノ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6-クロロ-7-ヨード-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1 -ジ オキシド ・6-クロロ-3-シアノメチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・5.7-ジクロロ-3-イソプロピルアミノ-6-トリフルオロメチル-4H-1,2,4-ベン ゾチアジアジン1,1-ジオキシド ・7-クロロ-3-(3-(1-H-イミダゾール-4-イル)プロピル)アミノ-4H-1,2.4-ベン ゾチアジアジン1,1-ジオキシド ・3-イソプロピルアミノ-6,7-ジメトキシ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・3-(1-アザビシクロ[2.2.2]オクタ-3-イル)アミノ-7-クココ-4H-1,2,4-ベンゾ チアジアジン1,1-ジオキシド ・6-クロロ-3-(1,2-ジメチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6-クロロ-3-(1,2-ジメチルプロピル)アミノ-7-スルファモイル-4H-1,2,4-ベ ンゾチアジアジン1,1-ジオキシド ・3-アニリノ-7-クロロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-クロロ-3-(ミダゾール-2-イル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・7-クロロ-3-(4-ピリジル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6-クロロ-3-イソブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-sec-ブチルアミノ-6-クロロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-クロロ-3-シクロヘキシルメチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオギシド ・6-フルオロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・3-シクロペンチルアミノ-6-フルオロ-4H-1,2,4ベンゾチアジアジン1,1-ジオ キシド ・7-クロロ-3-イソプロピルアミノ-5-ニトロ-4H-1,2,4-ベンゾチアジアジン1,1 -ジオキシド ・3-tert-ブチルアミノ-6-クロロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-ヨード-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6-クロロ-7-フルオロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1 ,1-ジオキシド ・3-イソプロピルアミノ-6-トリフルオロメチル-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・7-クロロ-3-シクロプロピルメチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・3-イソプロピルアミノ-7-メチル-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・5,7-ジブロモ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・6-アセチル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・3-アリルアミノ-6-クロロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-クロロ-3-(1-エチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6-クロロ-3-ブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-クロロ-3-ヘキシルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6,7-ジクロロ-3-(1,2-ジメチルプロピル)アミノ-4H-1,2,4--ベンゾチアジア ジン1,1-ジオキシド ・6,7-ジクロロ-3-(1-メチルブチル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・7-クロロ-3-(1,2-ジメチルプロピル)アミノ-2-メチル-2H-1,2,4-ベンゾチア ジアジン1,1-ジオキシド ・6,8-ジクロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・7-クロロ-3-イソプロピルアミノ-2-メチル-2H-1,2,4-ベンゾチアジアジン1,1 -ジオキシド ・3-イソプロピルアミノ-6-ベンゼンスルホニル-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・3-イソプロピルアミノ-6-メタンスルホニル-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・5-クロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・3-イソプロピルアミノ-6-メチル-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6-クロロ-3-イソプロピルアミノ-7-メチル-4H-1,2,4-ベンゾチアジアジン1,1 -ジオキシド ・6-エトキシカルボニルメチル-3-ィソプロピルアミノ-4H-1,2,4-ベンゾチアジ アジン1,1-ジオキシド ・6-カルボキシメチル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・8-クロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6-イソプロピル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-tert-ブチル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・3-イソプロピルアミノ-6-フェノキシ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・6-ヘキシル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・6-シクロヘキシル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・2-(3-イソプロピルアミノ-1,1-ジオキソ-1,4-ジヒドロ-1λ6,24-ベンゾチアジ アジン-6-イル)-アセタミド ・6-(3-シクロプロピル-1,2,4-オキサジアゾール-5-イル)メチル-3-イソプロピ ルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-シアノメチル-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(2-フェニルエチル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・3-sec-ブチルアミノ-7-ヨード-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-ヨード-3-(1,2-ジメチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-ヨード-3-(1,2,2-トリメチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・7-クロロ-3-シクロヘキシルメチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・(R)-7-クロロ-3-(1-シクロヘキシルエチル)アミノ-4H-1,2,4-ベンゾチアジ アジン1,1-ジオキシド ・(S)-7-クロロ-3-(1-シクロヘキシルエチル)アミノ-4H-1,2,4-ベンゾチアジ アジン1,1-ジオキシド ・(R)-7-クロロ-3-(1-フェニルエチル)アミノ-4H-1,2,4-ベンゾチアジアジン1 ,1-ジオキシド ・(S)-7-クロロ-3-(1-フェニルエチル)アミノ-4H-1,2,4-ベンゾチアジアジン1 ,1-ジオキシド ・3-シクロヘキシルメチルアミノ-7-ヨード-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・(R)-3-(1-シクロヘキシルエチル)アミノ-7-ヨード-4H-1,2,4-ベンゾチアジ アジン1,1-ジオキシド ・(S)-3-(1-ジクロヘキシルエチル)アミノ-7-ヨード-4H-1,2,4-ベンゾチアジ アジン1,1-ジオキシド ・3-ベンジルアミノ-7-ヨード-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・(R)-7-ヨード-3-(1-フェニルエチル)アミノ-4H-1,2,4-ベンゾチアジアジン1 ,1-ジオキシド ・(S)-7-ヨード-3-(1-フェニルエチル)アミノ-4H-1,2,4-ベンゾチアジアジン1 ,1-ジオ キシド ・3-sec-ブチルアミノ-7-ブロモ-4H,1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-ブロモ-3-(1,2-ジメチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-フルオロ-3-イソプロピルアミノ-4H-1,2.4-ベンゾチアジアジン1,1-ジオキ シド ・3-sec-ブチルアミノ-7-フルオロ-4H-1.2,4-ベンゾチアジアジン1.1-ジオキシ ド ・7-フルオロ-3-(1,2-ジメチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・7-ブロモ-3-シクロプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・7-クロロ-3-シクロブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-クロロ-3-(2,2,2-トリフルオロエチル)アミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・3-イソプロピルアミノ-7-ニトロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・3-アリルアミノ-7-クロロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-クロロ-3-(2-メトキシ-1-メチルエチル)アミノ-4H-1,2,4-ベンゾチアジア ジン1,1-ジオキシド ・7-クロロ-3-(1-エチルプロピル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・3-(1-エチルプロピル)アミノ-7-ヨード-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・3--sec-ブチルアミノ-7-ニトロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・3-(1,2.ジメチルプロピルアミノ)-7-ニトロ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-クロロ-3-(2-ヒドロキシプロピル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-クロロ-3-(2-ヒドロキシ-1-メチルエチル)アミノ-4H-1,2,4-ベンゾチアジ アジン1,1-ジオキシド ・3-(2-アミノエチル)アミノ-7-クロロ-4H.1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・7-クロロ-3(2,2-ジエトキシエチル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1 -ジオキシド ・3-エチルアミノ-7-フルオロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-フルオロ-3-プロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-シクロプロピルアミノ-7-フルオロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・3-シクロブチルアミノ-7-フルオロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・3-シクロペンチルアミノ-7-フルオロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・3-シクロプロピルメチル-7-フルオロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・3-アリルアミノ-7-フルオロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-フルオロ-3-(2-メトキシ-1-メチルエチル)アミノ-4H-1,2,4-ベンゾチアジ アジン1,1-ジオキシド ・6-クロロ-3-シクロブチルアミノ-4H-12,4-ベンゾチアジアジン1,1-ジオキシ ド ・6-クロロ-3-(2,2.2-トリフルオロエチル)アミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・7-ブロモ-3-メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-ブロモ-3-エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-ブロモ-3-シクロブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-ブロモ-3-(2,2,2-トリフルオロエチル)アミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・7-フルオロ-3-メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-クロロ-3-ヘキシルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6,7-ジクロロ-3-ヘキシルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・3-(2,2-ジエトキシエチル)アミノ-7-フルオロ-4H-1,2,4-ベンゾチアジアジン 1,1-ジ オキシド ・7-フルオロ-3-(2,2,2-リフルオロエチル)アミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・7-ブロモ-3-プロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-クロロ-3-シクロプロピルメチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・3-シクロプロピルメチルアミノ-7-ニトロ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・7-ニトロ-3-プロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-シクロブチルアミノ-7-ニトロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6,7-ジクロロ-3-シクロブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・7-アミノ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-アセタミド-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・3-シクロブチルアミノ-7-メチル-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・3-イソプロピルアミノ-7-メトキシ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・7-メトキシ-3-プロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-クロロ-3-(2-ホルミルアミノエチル)アミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・3-(2-アセチルアミノエチル)アミノ-7-クロロ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・5-クロロ-3-シクロブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・5-クロロ-3-プロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・5-クロロ-3-ヘキシルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-クロロ-3-オクチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6-クロロ-3-(1,5-ジメチルヘキシル)アミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・3-イソプロピルアミノ-7-トリフルオロメチル-4H-1,2,4-ベンゾチアジアジン 1.1-ジオキシド ・3-sec-ブチルアミノ-7-トリフルオロメチル-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン-7-カルボン酸1,1-ジオ キシド ・3-sec-ブチルアミノ-4H-1,2,4-ベンゾチアジアジン-7-カルボン酸1,1-ジオキ シド ・3-プロピルアミノ-7-トリフルオロメチル-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・3-シクロプロピルメチルアミノ-7-トリフルオロメチル-4H-1,2,4-ベンゾチア ジアジン1,1-ジオキシド ・3-プロピルアミノ-4H-1,2,4-ベンゾチアジアジン-7-カルボン酸1,1-ジオキシ ド ・7-クロロ-3-(ピリジン-2-イル)アミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・3-エチルアミノ-6,7-ジフルオロ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-フルオロ-3,6-ジ(イソプロピルアミノ)-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6,8-ジフルオロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6,7-ジフルオロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6,7,8-トリフルオロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-フルオロ-3-イソプロピルアミノ-6-メチル-4H-1,2,4-ベンゾチアジアジン1 ,1-ジオキシド ・7-クロロ-3-イソプロピルアミノ-6-メトキシ-4H-1,2,4-ベンゾチアジアジン1 ,1-ジオキシド ・6,8-ジクロロ-3-エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・6,8-ジクロロ-3-プロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6,8-ジクロロ-3-シクロプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6,8-ジクロロ-3-シクロプロピルメチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,8-ジクロロ-3-シクロブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・6,8-ジクロロ-3-シクロペンチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(4-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6-クロロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6-クロロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジンl,1-ジ オキシド ・6-クロロ-3-(4-ピリジル)メチルアミノ4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシ ド ・6-クロロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6-クロロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・6-クロロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-フルオロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・7-フルオロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・7-フルオロ-3-(4-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・7-フルオロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・5,7-フルオロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・7-フルオロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6-フルオロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6-フルオロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6-フルオロ-3-(4-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6-フルオロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6-フルオロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6-フルオロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・6.7-ジクロロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,7-ジクロロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,7-ジクロロ-3-(4-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,7-ジクロロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,7-ジクロロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,7-ジクロロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,8-ジクロロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,8-ジクロロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,8-ジクロロ-3-(4-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,8-ジクロロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,8-ジクロロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオキシド ・6,8-ジクロロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン1, 1-ジオ キシド ・6,7-ジフルオロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキンド ・6,7-ジフルオロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,7-ジフルオロ-3-(4-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,7-ジフルオロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,7-ジフルオロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,7-ジフルオロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,8-ジフルオロ-3-(2-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,8-ジフルオロ-3-(3-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,8-ジフルオロ-3-(4-ピリジル)メチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6,8-ジフルオロ-3-(2-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオキシド ・6.8-ジフルオロ-3-(3-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン 1.1-ジオキシド ・6,8-ジフルオロ-3-(4-ピリジル)エチルアミノ-4H-1,2,4-ベンゾチアジアジン 1,1-ジオギシド ・6,8-ビス(トリフルオロメチル)-3-(1,4-ジメチルペンチル)アミノ-4H-1,2,4- ベンゾチアジアジン1,1-ジオキシド ・6,8-ビス(トリフルオロメチル)-3-イソプロピルアミノ-4H-1,2,4-ベンゾチア ジアジン1.1-ジオキシド ・6,8-ビス(トリフルオロメチル)-3-シクロペンチルアミノ-4H-1,2,4-ベンゾチ アジアジン1,1-ジオキシド ・6,8-ビス(トリフルオロメチル)-3-シクロプロピルアミノ-4H-1,2,4-ベンゾチ アジアジン1,1-ジオキシド ・6,8-ビス(トリフルオロメチル)-3-プロピルアミノ-4H-1,2,4-ベンゾチアジア ジン1.1-ジオキシド ・6,8-ビス(トリフルオロメチル)-3-シクロブチルアミノ-4H-1,2,4-ベンゾチア ジアジン1.1-ジオキシド ・6.8-ビス(トリフルオロメチル)-3-エチルアミノ-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド。 11.請求項l〜10に記載の化合物であって、KATP調節カリウムチャンネ ルの開放剤として作用する化合物。 12.薬学的に許容可能なキャリアまたは希釈剤と共に、請求項1〜11の何 れか1項に記載の化合物、その薬学的に許容可能な酸もしくは塩との薬学的に許 容可能な塩、何れかの光学異性体もしくはラセミ混合物を含む光学異性体の混合 物、または何れかの互変異性体を含有する薬学的組成物。 13.過インスリン血症および糖尿病のような内分泌系疾患の治療に使用する ための薬学的組成物であって、薬学的に許容可能なキャリアまたは希釈剤と共に 、請求項1〜11の何れか1項に記載の化合物、その薬学的に許容可能な酸もし くは塩との薬学的に許容可能な塩、何れかの光学異性体もしくはラセミ混合物を 含む光学異性体の混合物、または何れかの互変異性体を含有する薬学的組成物。 14.請求項12または13に記載の薬学的組成物であって、経口単位と投与 形態または非経腸的単位投与形本である組成物。 15.請求項12または13に記載の薬学的組成物であって、前記化合物は、 1日当たり約0.05〜1000mg、好ましくは約0.1〜200mg、特に50〜200mgの範囲の 投与量で投与される組成物。 16.治療的用途に使用するための、請求項1〜11の何れか1項に記載の化 合物、その薬学的に許容可能な酸もしくは塩との薬学的に許容可能な塩、何れか の光学異性体もしくはラセミ混合物を含む光学異性体の混合物、または何れかの 互変異性体。 17.過インスリン血症および糖尿病のような内分泌系疾患の治療において治 療的に使用するための、請求項1〜11の何れか1項に記載の化合物、その薬学 的に許容可能な酸もしくは塩との薬学的に許容可能な塩、何れかの光学異性体も しくはラセミ混合物を含む光学異性体の混合物、または何れかの互変異性体。 18.医薬としての、請求項1〜11の何れか1項に記載の化合物、その薬学 的に許容可能な酸もしくは塩との薬学的に許容可能な塩、何れかの光学異性体も しくはラセミ混合物を含む光学異性体の混合物、または何れかの互変異性体の使 用。 19.医薬を製造するための、請求項1〜11の何れか1項に記載の化合物の 使用。 20.過インスリン血症および糖尿病のような内分泌系疾患の治療用医薬を製 造するための、治療的に使用するための、請求項1〜11の何れか1項に記載の 化合物、その薬学的に許容可能な酸もしくは塩との薬学的に許容可能な塩、何れ かの光学異性体もしくはラセミ混合物を含む光学異性体の混合物、または何れか の互変異性体の使用。 21.治療を必要としている患者において、過インスリン血症および糖尿病の ような内分泌系疾患を治療する方法であって、前記患者に対して、請求項1〜1 1の河れか1項に記載の化合物、その薬学的に許容可能な酸もしくは塩との薬学 的に許容可能な塩、何れかの光学異性体もしくはラセミ混合物を含む光学異性体 の混合物、または何れかの互変異性体の有効量を投与することを具備した方法。 22.医薬、特に過インスリン血症および糖尿病のような内分泌系疾患の治療 に使用される医薬を製造する方法であって、請求項1〜11の何れかに記載の式 Iの化合物またはその薬学的に許容可能な塩を、公定調剤薬の形態にすることを 具備した方法。 23.式Iの化合物を製造する方法であって: a)次式IIの化合物を次式IIIの化合物と反応させて、式Iの化合物を形成す ること; ここで、D,R1 1R4,R5,R12,R13,R14およびR15は上記で定義し た通りであり、またZはアルコキシ,アルキルチオ,ハロゲンのような脱離基、 好ましくはクロロ,ブロモ,ヨード,アミノ,トリメチルアミノ,イミダゾリル ,メチルスルフィニルまたはメチルスルホニルである: ここで、R2およびR3は上記で定義した通りである: または、 b)次式IVの化合物と式IIIの化合物またはその適切な塩とを、P2O5および 高沸点三級アミンまたはその適切な塩の存在下で反応させることにより、式Iの 化合物を形成すること; ここで、R1は水素で、D,R5,R12,R13,R14およびR15は上記で定 義したとおりであるか、或いは、R5はHで、R1 1,R12,R13,R14,R15および Dは上記で定義した通りである。 または、 c)式IVの化合物と式IIIの化合物またはその適切な塩とを、四塩化チタンお よび溶媒(またはトルエンおよびアニソールの混合物)の存在下で反応させて、 式Iの化合物を形成すること; ここで、R1は水素で、D,R5,R12,R13,R14およびR15は上記で定 義した通りであるか、或いはR5はHで、R1,R12,R13,R14,R15およびDは 上記定義した通りである。 または、 d)次式Vの化合物を次式IVの化合物と反応させて、式Iの化合物(ここで、 DはSO2であり、R2はHであり、R4およびR5は一緒になって結合を形成する )を形成すること: ここで、R1,R12,R13,R14およびR15は上記で定義した通りである 。 ここで、R3は上記で定義した通りである。 または、 e)次式Vの化合物を次式VIIの化合物と反応させることにより、一般式Iの 化合物(ここで、DはSO2、R2はH、R4およびR5一緒になって結合を形成す る)を形成すること; ここで、R1,R12,R13,R14およびR15は上記で定義した通りである 。 ここで、R3は上記で定義した通りである。 または、 f)次式Vの化合物を、次式VIIIの化合物またはその適切な塩と反応させて、 一般式Iの化合物(ここで、DはSO2であり、R4およびR5−緒になって結合 を形成し、またR2およびR3はHである)を形成すること; ここで、R1,R12,R13,R14およびR15上記で定義した通りである。 ここで、YはNHまたはSである。 または、 g)次式Vの化合物を、次式IXの化合物と反応させることにより、一般式Iの 化 合物(ここで、DはSO2、R2はH、R4およびR5は一緒になって結合を形成す る)を形成すること; ここで、R1 1,R12,R13,R14およびR15は上記で定義した通りであ る。 ここで、R3は上記で定義した通りである。 または、 h)次式Xの化合物を、塩基の存在下え次式XIの化合物またはその適切な塩と 反応させて、 ここで、R11はR1またはEtOC(=O)であり、R1,R12,R13,R14 およびR15は上記で定義した通りである。 ここで、R3は上記で定義した通りである。 次式XIまたはXIIの二つの構造の何れかを有する付加物、またはこれら二つの付 加物の混合物を形成し、これらの何れかを、例えば適切な溶媒中でホスゲンで処理することにより閉環し て、R11がR1であるときは、一般式Iの化合物(ここで、DはSO2であり、R2 はHであり、R4およびR5一緒になって結合を形成する)を形成し、R11がEtO C(=O)であるときは、一般式XIIIの化合物を形成し; また、次式XIIIの化合物を、例えば水性塩基中で加熱した後に酸で中和すること により、加水分解に続いて脱炭酸し、一般式I(ここで、DはSO2であり、R1 およびR2はHであり、R4およびR5は一緒になって結合を形成し、R3,R12,R13 ,R14およびR15は上記で定義した通りである)の化合物を形成すること; または、 j)次式XIVの化合物を、適切な溶媒中でチオカルボニルジイミダゾールと反 応させて、 ここで、R12,R13,R14およびR15は上記で定義した通りである。 次式XVの化合物を形成し、 これを次式IIIのアミンで処理して、一般式Iの化合物(ここで、DはSO2であ り、R1はHであり、R4およびR5は一緒になって結合を形成し、R2,R3,R12, R13,R14およびR15は上記で定義した通りである)を形成すること を具備する。 24.下記一般式Iの化合物、その薬学的に許容可能な酸もしくは塩基との塩 何れかの光学異性体もしくはラセミ混合物を含む光学異性体の混合物、または 何れかの互変異性体。 ここで、 R1およびR5は、独立に水素;ヒドロキシ;C1-6-アルコキシ;C3-6-シクロア ルキル[任意にC1-6-アルキル,ハロゲン,ヒドロキシもしくはC1-6-アルコキ シで弛緩される];またはC1-6-アルキル,C2-6-アルケニルもしくはC2-6-アル キニル[任意にハロゲンで置換される]であることができ、またよびR4は水素 であるか;或いは、 R4はR5と一緒に、式Iにおける原子2と原子3との間の二重結合の一つの結 合を表し、且つR1は上記で定義した通りであるか;或いは、 R4はR1と一緒に、式Iにおける原子3と原子4との間の二重結合の一つの結 合を表し、且つR5は上記で定義した通りであり; Dは-S(=O)2-または-S(=O)-を表し; R2は水素;ヒドロキシ;C1-6アルコキシ;C3-6-シクロアルキル[C1-6-アル キル,ハロゲン,ヒドロキシもしくはC1-6-アルコキシで任意に置換される]; または任意にハロゲンでモノ置換もしくはポリ置換された、C1-6-アルキル,C2 -6 -アルケニルもしくはC2-6-アルキニルであり; R3は、R8;-OR8;-C(=X)R8;ハロゲン,ヒドロキシ,C1-6-アルキル,C1- 6 -アルコキシ,アリーロキシ,アリールアルコキシ,ニトロ,アミノ,C1-6-モ ノアルキル-もしくはジアルキルアミノ,シアノ,オキソ,アシルもしくはC1-6 -アルコキシカルボニルで任意にモノ置換もしくはポリ置換された、ビシクロア ルキル,アリール,ヘテロアリール,アリールアルキルもしくはヘテロアリール アルキル;またはC1-6-アルキルで置換されたアリールであり; R8は水素;C3-6-シクロアルキルもしくは(C3-6-シクロアルキル)C1-6-アル キル[該C3-6-シクロアルキル基は圧意に、C1-6-アルキル,ハロゲン,ヒドロ キシもしくは C1-6-アルコキシでモノ置換もしくはポリ置換されていてもよい];1以上の窒 素原子、酸素原子もしくは硫黄原子を有する飽和の3〜6員環系;または直鎖もし くは分岐鎖のC1-12-アルキル[任意に、ハロゲン,ヒドロキシ,C1-6-アルコキ シ,C1-6-アルキルチオ,アリール,アリーロキシ,アリールアルコキシ,ニト ロ,アミノ,C1-6-モノアルキルもしくはジアルキルアミノ,シアノ,オキソ, ホルミル,アシル,カルボキシ,C1-6-アルコキシカルボニルもしくはカルバモ イルで置換される]; X1は、OまたはSであり; R9は水素;C1-6-アルキル;C2-6-アルケニル;C3-6-シクロアルキル[任意に C1-6アルキル,ハロゲン,ヒドロキシもしくはC1-6-アルコキシで置換される ]であるか;或いは、 R8およびR9は、窒素原子と一緒に単環もしくは2環式の3-12員環系(ここで 、1以上の炭素原子は窒素原子,酸素原子もしくは硫黄原子と交換されてもよく 、またこれら環系は任意にハロゲン,C1-6-アルキル,ヒドロキシ,C1-6-アルコ キシ,C1-6-アルコキシ-C1-6-アルキル,ニトロ,アミノ,シアノ,トリフルオ ロメチル,C1-6-モノアルキル-もしくはジアルキルアミノ,オキソで置換される )を形成し;或いは、 R3は、 [ここで、n,m,pは独立して0,1,2,3であり、またR10は水素;ヒドロキシ;C1-6- アルコキシ;C3-6-シクロアルキル(任意に、C1-6-アルキル,ハロゲン,ヒド ロキシもしくはC1-6アルコキシでモノ置換もしくはポリ置換される);または 任意にハロゲンでモノ置換もしくはポリ置換されたC1-6-アルキル,C2-6-アル ケニルもしくはC2-6-アルキニルである]であるか;或いは、 R2およびR3は、窒素原子と一緒に単環もしくは2環式の3-12員環系(ここで 、1以上の炭素原子は窒素原子,酸素原子もしくは硫黄原子と交換されてもよく 、ま たこれら環系は圧意にハロゲン,C1-6-アルキル,ヒドロキシ,C1-6-アルコキシ ,C1-6-アルコキシ-C1-6-アルキル,ニトロ,アミノ,シアノ,トリフルオロメ チル,C1-6-モノアルキル,もしくはジアルキルアミノ,オキソで置換される) を形成する; R12,R13,R14,R15は独立に、水素;ハロゲン;C1-6-アルキル;ヒドロキシ; C1-6-アルコキシ;C1-6-アルコキシ-C1-6-アルキル;ニトロ;アミノ;シアノ;ペ ルハロメチル;C1-6モノアルキル-もしくはジアルキルアミノ;スルファモイル; C1-6-アルキルチオ;C1-6-アルキルスルホニル;C1-6-アルキルスルフィニル; C1-6-アルキルカルボニルアミノ;アリールチオ,アリールスルフィニル,アリー ルスルホニル[ここで、アリール基は任意にC1-6-アルキル,ハロゲン,ヒドロ キシもしくはC1-6-アルコキシでモノ置換もしくはポリ置換される];C1-6-ア ルコキシカルボニル;カルバミル;C1-6-モノアルキル-もしくはジアルキルアミ ノカルボニル;C1-6-モノアルキル-もしくはジアルキルアミノチオカルボニル; ウレイド;C1-6-モノアルキル-もしくはジアルキルアミノカルボニルアミノ,チ オウレイド;C1-6-モノアルキル-もしくはジアルキルアミノチオカルボニルアミ ノ;C1-6-モノアルキル-もしくはジアルキルアミノスルホニル;カルボキシ;アシ ル;アリール,アリールアルキル[これらアリール基は任意に、C1-6-アルキル ,ハロゲン,ヒドロキシもしくはC1-6-アルコキシでモノ置換もしくはポリ置換 される];または窒素を含む5-6員環[任意にフェニルもしくはC1-6-アルキル で置換される]である: 但し、以下の化合物; ・3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-イソブチルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-(2-エチルヘキシルアミノ)-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-シクロプロビルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-シクロヘキシルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・7-クロロ-3-(1,2,2-トリメチルプロピルアミノ)-4H-1,2,4-ベンゾチアジアジ ン1,1-ジオキシド ・7-クロロ-3-(1,2-ジメチルプロピルアミノ)-4H-1,2,4-ベンゾチアジアジン1, 1-ジオ キシド ・7-クロロ-3-(1-メチルプロピルアミノ)-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・7-クロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-クロロ-3-シクロロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・7-クロロ-3-シクロヘキシルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・6-クロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシ ド ・6-クロロ-3-シクロプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・6,7-ジクロロ-3-イソプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジオ キシド ・6,7-ジクロロ-3-シクロプロピルアミノ-4H-1,2,4-ベンゾチアジアジン1,1-ジ オキシド ・3-イソブチルアミノ-7-メチル-4H-1,2,4-ベンゾチアジアジン1,1-ジオキシド ・3-シクロペンチルアミノ-7-メチル-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・3-シクロヘキシルアミノ-6-トリフルオロメチル-4H-1,2,4-ベンゾチアジアジ ン11-ジオキシド ・3-(N-シクロヘキシル-N-メチルアミノ)-4H-1,2,4-ベンゾチアジアジン1,1- ジオキシド ・3-シクロヘキシルアミノ-4-メチル-4H-1,2,4-ベンゾチアジアジン1,1-ジオキ シド ・3-シクロヘキシルアミノ-2-メチル-2H-1,2,4-ベンゾチアジアジン1,1-ジオキ シドは除く。 25.ここに開示した何れかの新規な特徴またはこれら特徴の組み合わせ。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK0693/96 | 1996-06-21 | ||
DK69396 | 1996-06-21 | ||
DK145196 | 1996-12-19 | ||
DK1451/96 | 1996-12-19 | ||
PCT/DK1997/000266 WO1997049692A1 (en) | 1996-06-21 | 1997-06-19 | 1,2,4-benzothiadiazine derivatives, their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000512641A true JP2000512641A (ja) | 2000-09-26 |
Family
ID=26064470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10502127A Withdrawn JP2000512641A (ja) | 1996-06-21 | 1997-06-19 | 1,2,4―ベンゾチアジアジン誘導体、その製造および使用 |
Country Status (18)
Country | Link |
---|---|
US (1) | US6242443B1 (ja) |
EP (1) | EP0906297B1 (ja) |
JP (1) | JP2000512641A (ja) |
KR (1) | KR20000022087A (ja) |
CN (1) | CN1081633C (ja) |
AT (1) | ATE260266T1 (ja) |
AU (1) | AU737920B2 (ja) |
BR (1) | BR9709858A (ja) |
CA (1) | CA2258100A1 (ja) |
CZ (1) | CZ413198A3 (ja) |
DE (1) | DE69727806T2 (ja) |
ES (1) | ES2216155T3 (ja) |
HU (1) | HUP9904032A3 (ja) |
IL (1) | IL127368A0 (ja) |
MX (1) | MXPA98010773A (ja) |
NO (1) | NO985979L (ja) |
PL (1) | PL330815A1 (ja) |
WO (1) | WO1997049692A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0977738B1 (en) * | 1997-04-28 | 2005-11-16 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer |
AU1555999A (en) * | 1997-12-19 | 1999-07-12 | Novo Nordisk A/S | 1,2,4-benzothiadiazine derivatives, their preparation and use |
US6943159B1 (en) | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
AU2001265840A1 (en) * | 2000-06-26 | 2002-01-08 | Novo-Nordisk A/S | Use of potassium channel agonists for reducing fat food comsumption |
JP2004518726A (ja) * | 2001-02-14 | 2004-06-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ベンゾチアジアジンマトリックスメタロプロテイナーゼ阻害剤 |
US7282519B2 (en) | 2003-08-28 | 2007-10-16 | Nitromed, Inc. | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use |
US7396829B2 (en) | 2005-02-24 | 2008-07-08 | Nitromed, Inc. | Nitric oxide enhancing diuretic compounds, compositions and methods of use |
TWI395749B (zh) * | 2006-06-22 | 2013-05-11 | Anadys Pharmaceuticals Inc | 吡咯并〔1,2-b〕嗒酮化合物 |
US20090257979A1 (en) * | 2008-04-15 | 2009-10-15 | Intermune, Inc. | Novel Inhibitors of Hepatitis C Virus Replication |
EP2395987A1 (en) | 2009-02-12 | 2011-12-21 | Coöperatieve Mirzorg U.A., Arnhem | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
US20120100229A1 (en) * | 2009-03-27 | 2012-04-26 | Yale University | Treatment and Prevention of White Matter Injury with KATP Channel Activators |
TW201121968A (en) * | 2009-11-09 | 2011-07-01 | Intermune Inc | Novel inhibitors of hepatitis C virus replication |
EP3099304A4 (en) | 2014-01-31 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Novel therapeutics for the treatment of glaucoma |
WO2017098421A1 (en) * | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
US11926604B2 (en) | 2018-05-11 | 2024-03-12 | University Of Florida Research Foundation, Incorporated | Myelination stimulator compounds, and methods of treatment |
NL2022291B1 (en) * | 2018-12-21 | 2020-07-21 | Academisch Ziekenhuis Leiden | Compound for Use in Treatment and Prevention of Type I Diabetes |
CN110903264B (zh) * | 2019-12-26 | 2021-06-18 | 苏州大学 | 一种制备二氮嗪的方法 |
US20230219912A1 (en) * | 2020-05-19 | 2023-07-13 | Board Of Regents Of The University Of Nebraska | Halogenated benzothiadiazines for the treatment of cancer |
WO2024086252A1 (en) * | 2022-10-18 | 2024-04-25 | Rhythm Pharmaceuticals, Inc. | Novel atp-sensitive potassium channel potentiators, their preparation and use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3269906A (en) | 1966-08-30 | Imino-j,x-dihydro-l,z,x-benzothiadiazine- i,i-dioxides | ||
GB847176A (en) * | 1958-06-20 | 1960-09-07 | Lepetit Spa | Benzothiadiazine compounds |
CA1056827A (en) * | 1974-10-29 | 1979-06-19 | Haruki Nishimura | 1,2,4-benzothiadiazine 1,1-dioxide derivatives |
SE402773B (sv) | 1976-04-20 | 1978-07-17 | Dainippon Pharmaceutical Co | Forfarande for framstellning av 1,2,4-bensotiadiazin-1,1-dioxid-derivat |
DE2757925A1 (de) * | 1977-12-24 | 1979-06-28 | Bayer Ag | Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2757922A1 (de) * | 1977-12-24 | 1979-06-28 | Bayer Ag | Substituierte alkylenamino-1.2.4- benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
-
1997
- 1997-06-17 US US08/877,456 patent/US6242443B1/en not_active Expired - Fee Related
- 1997-06-19 BR BR9709858A patent/BR9709858A/pt unknown
- 1997-06-19 PL PL97330815A patent/PL330815A1/xx unknown
- 1997-06-19 HU HU9904032A patent/HUP9904032A3/hu unknown
- 1997-06-19 AU AU31664/97A patent/AU737920B2/en not_active Ceased
- 1997-06-19 CZ CZ984131A patent/CZ413198A3/cs unknown
- 1997-06-19 ES ES97927017T patent/ES2216155T3/es not_active Expired - Lifetime
- 1997-06-19 AT AT97927017T patent/ATE260266T1/de not_active IP Right Cessation
- 1997-06-19 DE DE1997627806 patent/DE69727806T2/de not_active Expired - Lifetime
- 1997-06-19 KR KR1019980710491A patent/KR20000022087A/ko not_active Application Discontinuation
- 1997-06-19 CN CN97195677A patent/CN1081633C/zh not_active Expired - Fee Related
- 1997-06-19 EP EP97927017A patent/EP0906297B1/en not_active Expired - Lifetime
- 1997-06-19 IL IL12736897A patent/IL127368A0/xx unknown
- 1997-06-19 JP JP10502127A patent/JP2000512641A/ja not_active Withdrawn
- 1997-06-19 MX MXPA98010773A patent/MXPA98010773A/es unknown
- 1997-06-19 CA CA002258100A patent/CA2258100A1/en not_active Abandoned
- 1997-06-19 WO PCT/DK1997/000266 patent/WO1997049692A1/en not_active Application Discontinuation
-
1998
- 1998-12-18 NO NO985979A patent/NO985979L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20000022087A (ko) | 2000-04-25 |
IL127368A0 (en) | 1999-10-28 |
AU3166497A (en) | 1998-01-14 |
BR9709858A (pt) | 1999-08-10 |
WO1997049692A1 (en) | 1997-12-31 |
HUP9904032A3 (en) | 2001-11-28 |
CN1222910A (zh) | 1999-07-14 |
DE69727806T2 (de) | 2005-01-13 |
EP0906297B1 (en) | 2004-02-25 |
CA2258100A1 (en) | 1997-12-31 |
ES2216155T3 (es) | 2004-10-16 |
MXPA98010773A (es) | 2002-06-11 |
NO985979D0 (no) | 1998-12-18 |
ATE260266T1 (de) | 2004-03-15 |
HUP9904032A2 (hu) | 2000-03-28 |
US6242443B1 (en) | 2001-06-05 |
NO985979L (no) | 1999-02-19 |
CZ413198A3 (cs) | 1999-06-16 |
CN1081633C (zh) | 2002-03-27 |
PL330815A1 (en) | 1999-06-07 |
DE69727806D1 (de) | 2004-04-01 |
EP0906297A1 (en) | 1999-04-07 |
AU737920B2 (en) | 2001-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU757693B2 (en) | Fused 1,2,4-thiadiazine derivatives, their preparation and use | |
JP3071832B2 (ja) | 縮合した1,2,4−チアジアジン及び縮合した1,4−チアジン誘導体、これらの製造および使用 | |
US6225310B1 (en) | Fused 1,2,4-thiadiazine derivatives, their preparation and use | |
JP2000512641A (ja) | 1,2,4―ベンゾチアジアジン誘導体、その製造および使用 | |
JP2513989B2 (ja) | 新規なピリドチアジアジン、それらの製造法、およびそれらを含む医薬組成物 | |
JP2002533347A (ja) | 融合1,2,4−チアジアジン誘導体、その製造及び使用 | |
US5792764A (en) | Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, their preparation and use | |
WO1999032495A1 (en) | Pyrido 1,2,4-thiadiazine derivatives, their preparation and use | |
RU2199542C2 (ru) | Производные конденсированного 1,2,4-тиадиазина и конденсированного 1,4-тиазина, их получение и использование | |
CZ200044A3 (cs) | Kondenzovaný 1,4-thiazinový derivát, způsob jeho výroby a farmaceutický prostředek ho f obsahující | |
WO1999032467A1 (en) | 1,2,4-benzothiadiazine derivatives, their preparation and use | |
WO1999032494A1 (en) | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040519 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071225 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080325 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080512 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080416 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081001 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081023 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081030 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20110112 |